Lung cancer: current therapies and new targeted treatments

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending on stage and regional differences. In this Seminar, we disc...

Full description

Saved in:

Bibliographic Details
Published in	The Lancet (British edition) Vol. 389; no. 10066; pp. 299 - 311
Main Authors	Hirsch, Fred R, Scagliotti, Giorgio V, Mulshine, James L, Kwon, Regina, Curran, Walter J, Wu, Yi-Long, Paz-Ares, Luis
Format	Journal Article
Language	English
Published	England Elsevier Ltd 21.01.2017 Elsevier Limited
Subjects	Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Combined Modality Therapy Early Detection of Cancer Humans Immunotherapy Internal Medicine Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - therapy Medical screening Mutation Oncology Prevention Survival Survival Rate
Online Access	Get full text

Cover

Loading…

Abstract	Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg—patients with poor performance status and elderly patients—are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
AbstractList	Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg--patients with poor performance status and elderly patients--are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar. Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar. Summary Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg—patients with poor performance status and elderly patients—are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
Author	Mulshine, James L Wu, Yi-Long Kwon, Regina Paz-Ares, Luis Hirsch, Fred R Scagliotti, Giorgio V Curran, Walter J
Author_xml	– sequence: 1 givenname: Fred R surname: Hirsch fullname: Hirsch, Fred R email: fred.hirsch@ucdenver.edu organization: Department of Medicine, Division of Medical Oncology and Department of Pathology, University of Colorado Cancer Center, Denver, CO, USA – sequence: 2 givenname: Giorgio V surname: Scagliotti fullname: Scagliotti, Giorgio V organization: Division of Oncology, Department of Oncology, San Luigi Hospital-Orbassano, University of Torino, Orbassano, Italy – sequence: 3 givenname: James L surname: Mulshine fullname: Mulshine, James L organization: Rush University Medical Center, Chicago, IL, USA – sequence: 4 givenname: Regina surname: Kwon fullname: Kwon, Regina organization: School of Medicine, University of Colorado, Denver, CO, USA – sequence: 5 givenname: Walter J surname: Curran fullname: Curran, Walter J organization: Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA – sequence: 6 givenname: Yi-Long surname: Wu fullname: Wu, Yi-Long organization: Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China – sequence: 7 givenname: Luis surname: Paz-Ares fullname: Paz-Ares, Luis organization: Medical Oncology Department, Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/27574741$$D View this record in MEDLINE/PubMed
BookMark	eNqNkV1rFDEUhkOp2G3tT1AGelMvxuY72YqKlH7Bghcq9C6kydmadjazJhml_97MblthQepVSHjeJ4f37KLt2EdA6DXB7wgm8ugrJhy3UjF5SORbhqdCt3oLTQhXvBVcXW2jyROyg3ZzvsUYc4nFS7RDlVCVIxN0PBviTeNsdJCOGzekBLE05QckuwyQGxt9E-F3U2y6gQK-KQlsWVQov0Iv5rbLsP9w7qHvZ6ffTi7a2Zfzy5PPs9ZJLUpLGPOeW-HmTDIhNOfeSjxn11rWN40VOKaomirqqLKUY2uBUiu81lQ6rNkeOlx7l6n_OUAuZhGyg66zEfohG6JFDTMiSUUPNtDbfkixTlcpSWo3RE0r9eaBGq4X4M0yhYVN9-axlQq8XwMu9TknmBsXii2hjyXZ0BmCzbgDs9qBGQs29bbagRnnFRvpxw-ey31a56CW-StAMtkFqIvxIYErxvfhWcPHDYPrQgzOdndwD_lvFyZTg9eS0UHkyjAKPvxb8B8D_AG2hMOA
CODEN	LANCAO
CitedBy_id	crossref_primary_10_3389_fonc_2022_1071100 crossref_primary_10_3389_fonc_2020_611054 crossref_primary_10_1093_pcmedi_pbae006 crossref_primary_10_3892_ol_2023_14105 crossref_primary_10_1186_s12885_019_5400_3 crossref_primary_10_1080_01621459_2023_2210337 crossref_primary_10_3389_fonc_2022_986236 crossref_primary_10_1038_s41389_019_0170_y crossref_primary_10_1002_cam4_7314 crossref_primary_10_1002_adhm_202100078 crossref_primary_10_1038_s41416_023_02476_8 crossref_primary_10_7759_cureus_41319 crossref_primary_10_3389_fphar_2022_761785 crossref_primary_10_3390_cancers11030298 crossref_primary_10_1016_j_heliyon_2023_e16736 crossref_primary_10_1016_j_pharmthera_2022_108333 crossref_primary_10_3389_fgene_2023_1256756 crossref_primary_10_1038_s41392_021_00745_7 crossref_primary_10_1186_s12931_023_02423_4 crossref_primary_10_1097_MD_0000000000020263 crossref_primary_10_1016_j_tiv_2023_105703 crossref_primary_10_1186_s13000_020_01048_1 crossref_primary_10_1177_08850666211061312 crossref_primary_10_2147_OTT_S255195 crossref_primary_10_1080_20013078_2020_1790158 crossref_primary_10_1016_j_amjms_2022_12_014 crossref_primary_10_3389_fphar_2023_1217213 crossref_primary_10_1016_j_bcp_2024_116414 crossref_primary_10_3389_fimmu_2019_02801 crossref_primary_10_1109_TIM_2023_3315365 crossref_primary_10_1002_kjm2_12389 crossref_primary_10_3390_ijms23031240 crossref_primary_10_1002_term_3275 crossref_primary_10_1016_j_ejca_2017_07_036 crossref_primary_10_3390_cancers13133229 crossref_primary_10_3390_cancers14235923 crossref_primary_10_1186_s12951_024_02967_7 crossref_primary_10_1016_j_drup_2022_100888 crossref_primary_10_1097_MS9_0000000000001865 crossref_primary_10_1186_s12906_023_04245_9 crossref_primary_10_3389_fphar_2019_01457 crossref_primary_10_1159_000537754 crossref_primary_10_1183_13993003_01907_2019 crossref_primary_10_1186_s13643_021_01585_w crossref_primary_10_2147_OTT_S241816 crossref_primary_10_3892_ol_2017_7428 crossref_primary_10_1002_cncy_22434 crossref_primary_10_1111_1759_7714_14848 crossref_primary_10_1134_S1070363222100231 crossref_primary_10_3390_ijms21228480 crossref_primary_10_2147_PGPM_S264545 crossref_primary_10_18632_oncotarget_23279 crossref_primary_10_1093_annonc_mdx516 crossref_primary_10_2147_IJGM_S340615 crossref_primary_10_1158_1940_6207_CAPR_19_0211 crossref_primary_10_1016_j_lungcan_2019_07_001 crossref_primary_10_1016_j_tranon_2021_101309 crossref_primary_10_1177_15347354221144312 crossref_primary_10_1016_j_ajpath_2022_03_005 crossref_primary_10_1007_s12672_024_01032_x crossref_primary_10_1016_j_ymthe_2023_09_015 crossref_primary_10_1124_jpet_117_240986 crossref_primary_10_3892_etm_2025_12829 crossref_primary_10_3390_nu11122989 crossref_primary_10_1515_cclm_2022_1108 crossref_primary_10_3389_fonc_2024_1402994 crossref_primary_10_1038_s41388_018_0482_y crossref_primary_10_1016_j_phymed_2024_155690 crossref_primary_10_1007_s11033_022_07509_8 crossref_primary_10_1016_j_sjbs_2022_02_016 crossref_primary_10_1016_j_amjsurg_2023_02_016 crossref_primary_10_1248_cpb_c20_00086 crossref_primary_10_1016_j_lfs_2020_117366 crossref_primary_10_4103_wjtcm_wjtcm_42_20 crossref_primary_10_1111_1759_7714_13976 crossref_primary_10_1111_1759_7714_14822 crossref_primary_10_1038_s41389_022_00400_y crossref_primary_10_1155_2022_6495301 crossref_primary_10_1038_s41598_020_60559_5 crossref_primary_10_1016_j_mrfmmm_2024_111873 crossref_primary_10_1007_s10495_022_01720_5 crossref_primary_10_3389_fonc_2020_00715 crossref_primary_10_3390_ijms21249376 crossref_primary_10_1038_s41420_022_01283_z crossref_primary_10_1093_hmg_ddae110 crossref_primary_10_1177_1533033820945807 crossref_primary_10_1002_adma_202308977 crossref_primary_10_12677_ACM_2023_1361409 crossref_primary_10_1002_cam4_5103 crossref_primary_10_2174_1386207326666230821112230 crossref_primary_10_1080_09168451_2019_1694404 crossref_primary_10_1093_jpp_rgab049 crossref_primary_10_1186_s13019_024_02609_x crossref_primary_10_1186_s40364_022_00400_5 crossref_primary_10_1007_s10528_022_10234_3 crossref_primary_10_1039_D2BM01825J crossref_primary_10_1016_j_cbi_2022_109966 crossref_primary_10_3390_nano12183138 crossref_primary_10_1016_j_ejim_2017_03_018 crossref_primary_10_1080_14737159_2017_1372196 crossref_primary_10_2174_1573406419666221219144804 crossref_primary_10_1002_cnr2_1578 crossref_primary_10_1186_s13046_019_1162_7 crossref_primary_10_1021_acs_jmedchem_9b01566 crossref_primary_10_1016_j_mrfmmm_2024_111856 crossref_primary_10_1111_1759_7714_14801 crossref_primary_10_1007_s40134_019_0330_z crossref_primary_10_1186_s12859_023_05302_3 crossref_primary_10_2147_OTT_S248492 crossref_primary_10_1513_AnnalsATS_201801_045OC crossref_primary_10_1080_21655979_2022_2063537 crossref_primary_10_3389_fonc_2023_1235679 crossref_primary_10_3390_curroncol29090481 crossref_primary_10_1016_j_ebiom_2024_105019 crossref_primary_10_18632_oncotarget_27675 crossref_primary_10_1038_s41598_024_61804_x crossref_primary_10_1016_j_prp_2021_153541 crossref_primary_10_1038_s41419_024_06899_w crossref_primary_10_3390_biomedicines9010048 crossref_primary_10_3233_THC_240660 crossref_primary_10_3389_fcell_2022_815596 crossref_primary_10_1016_j_neo_2024_101004 crossref_primary_10_1002_cbin_11531 crossref_primary_10_1080_15592294_2019_1573066 crossref_primary_10_1002_anie_202009983 crossref_primary_10_3389_fphar_2019_00982 crossref_primary_10_1155_2023_9658912 crossref_primary_10_1016_j_csbj_2022_03_035 crossref_primary_10_1038_s41598_023_39000_0 crossref_primary_10_1186_s12935_021_01764_8 crossref_primary_10_1155_2022_8069858 crossref_primary_10_18632_oncotarget_25049 crossref_primary_10_1186_s12890_023_02755_3 crossref_primary_10_1038_s41388_021_02134_4 crossref_primary_10_1080_21691401_2019_1699813 crossref_primary_10_1111_crj_70000 crossref_primary_10_18632_aging_203004 crossref_primary_10_3892_ol_2020_11512 crossref_primary_10_1016_j_bbadis_2023_166924 crossref_primary_10_1158_1535_7163_MCT_20_0076 crossref_primary_10_1177_0300060520937162 crossref_primary_10_1038_s41419_021_03804_7 crossref_primary_10_1016_j_canlet_2017_06_013 crossref_primary_10_18632_aging_103191 crossref_primary_10_1016_j_dib_2024_111167 crossref_primary_10_1080_15384047_2024_2373447 crossref_primary_10_3389_fimmu_2024_1473288 crossref_primary_10_1111_jcmm_15887 crossref_primary_10_3233_CBM_190094 crossref_primary_10_1002_cncy_22483 crossref_primary_10_1111_crj_70013 crossref_primary_10_2174_1568009621666210415094350 crossref_primary_10_1007_s00408_019_00284_7 crossref_primary_10_1177_1533033820985868 crossref_primary_10_1590_1678_4685_gmb_2022_0023 crossref_primary_10_12677_ACM_2022_12111435 crossref_primary_10_1016_j_jep_2023_116943 crossref_primary_10_1177_01939459251325490 crossref_primary_10_1002_cbin_11158 crossref_primary_10_1016_j_hermed_2022_100608 crossref_primary_10_1002_cam4_3379 crossref_primary_10_1016_j_cbi_2019_108820 crossref_primary_10_1111_cas_15987 crossref_primary_10_1016_j_taap_2025_117226 crossref_primary_10_3389_fonc_2021_664290 crossref_primary_10_1002_ptr_7033 crossref_primary_10_1038_s41392_024_01889_y crossref_primary_10_1016_j_rce_2022_05_006 crossref_primary_10_3389_fimmu_2020_01680 crossref_primary_10_3892_ol_2018_9022 crossref_primary_10_1002_adhm_202300105 crossref_primary_10_1002_jcb_27996 crossref_primary_10_1016_j_cclet_2021_11_076 crossref_primary_10_3389_fonc_2020_00349 crossref_primary_10_1016_j_canlet_2020_10_032 crossref_primary_10_1177_15347354211037917 crossref_primary_10_1016_j_wjam_2022_07_004 crossref_primary_10_1016_j_wjam_2022_07_003 crossref_primary_10_2217_nnm_2023_0015 crossref_primary_10_1111_jcmm_15866 crossref_primary_10_1016_j_biopha_2023_116014 crossref_primary_10_3389_fonc_2022_1057646 crossref_primary_10_1186_s12951_023_02218_1 crossref_primary_10_1002_hsr2_1522 crossref_primary_10_1111_jcmm_14532 crossref_primary_10_1186_s13046_020_01819_0 crossref_primary_10_1002_ddr_70020 crossref_primary_10_2174_1570180817999200513091613 crossref_primary_10_3389_fonc_2023_1034752 crossref_primary_10_1016_S0140_6736_24_01029_8 crossref_primary_10_1021_acsnano_3c08335 crossref_primary_10_1016_j_canlet_2023_216165 crossref_primary_10_3390_cells11233737 crossref_primary_10_1016_j_canlet_2019_09_014 crossref_primary_10_1111_1759_7714_15303 crossref_primary_10_3390_ijms231810415 crossref_primary_10_1016_j_ejca_2024_114233 crossref_primary_10_1038_s41419_023_06194_0 crossref_primary_10_1186_s13045_022_01285_5 crossref_primary_10_1016_j_smaim_2024_04_001 crossref_primary_10_3390_cancers17020285 crossref_primary_10_1007_s00259_020_05005_4 crossref_primary_10_1186_s12885_021_08407_1 crossref_primary_10_3389_fonc_2020_568939 crossref_primary_10_3390_cancers13122942 crossref_primary_10_1007_s41127_024_00079_5 crossref_primary_10_1186_s12859_019_2739_z crossref_primary_10_1186_s12935_023_03082_7 crossref_primary_10_1016_j_bcp_2024_116068 crossref_primary_10_1016_j_ijpharm_2024_125113 crossref_primary_10_1016_j_arr_2024_102576 crossref_primary_10_1080_07853890_2021_2000634 crossref_primary_10_3389_fonc_2021_676202 crossref_primary_10_18632_aging_204770 crossref_primary_10_3389_fonc_2021_608113 crossref_primary_10_1097_MD_0000000000025992 crossref_primary_10_3389_fphar_2019_00556 crossref_primary_10_1016_j_intimp_2024_112157 crossref_primary_10_1007_s10238_024_01409_w crossref_primary_10_1111_jcmm_16773 crossref_primary_10_1177_1934578X211050521 crossref_primary_10_1634_theoncologist_2020_0234 crossref_primary_10_1177_02841851221126596 crossref_primary_10_1016_j_actbio_2025_02_012 crossref_primary_10_1016_j_lungcan_2022_04_002 crossref_primary_10_1111_1759_7714_14432 crossref_primary_10_1111_1759_7714_13101 crossref_primary_10_15324_kjcls_2023_55_1_16 crossref_primary_10_32604_biocell_2023_030032 crossref_primary_10_3389_fgene_2024_1419099 crossref_primary_10_1016_j_atssr_2025_01_008 crossref_primary_10_1186_s43556_022_00107_x crossref_primary_10_1080_13696998_2024_2444781 crossref_primary_10_3390_pharmaceutics15122777 crossref_primary_10_1186_s12935_021_02268_1 crossref_primary_10_1016_j_omtn_2020_12_023 crossref_primary_10_1016_j_jtcvs_2019_10_105 crossref_primary_10_1038_s42003_022_03016_5 crossref_primary_10_1111_1759_7714_13558 crossref_primary_10_3389_fphar_2025_1533493 crossref_primary_10_1016_j_dmpk_2024_101050 crossref_primary_10_1016_j_intimp_2021_107594 crossref_primary_10_3389_fmed_2023_1152421 crossref_primary_10_3389_fimmu_2022_1034992 crossref_primary_10_3389_fcell_2023_1249174 crossref_primary_10_3892_ijmm_2025_5512 crossref_primary_10_3390_molecules28186532 crossref_primary_10_3390_cancers11091245 crossref_primary_10_1016_j_ygeno_2021_06_013 crossref_primary_10_1155_2022_2989200 crossref_primary_10_1159_000501726 crossref_primary_10_2174_0118715206295371240724092314 crossref_primary_10_1016_j_yexcr_2022_113305 crossref_primary_10_3390_ijms20082005 crossref_primary_10_1053_j_semtcvs_2020_12_012 crossref_primary_10_1007_s13577_021_00647_4 crossref_primary_10_3389_fphar_2022_997842 crossref_primary_10_1080_0284186X_2022_2042474 crossref_primary_10_1002_fsn3_2636 crossref_primary_10_3390_biom12081040 crossref_primary_10_1136_esmoopen_2018_000406 crossref_primary_10_1016_j_heliyon_2023_e23828 crossref_primary_10_1097_MD_0000000000025046 crossref_primary_10_3389_fonc_2022_1035808 crossref_primary_10_1186_s13046_023_02692_3 crossref_primary_10_1016_j_biopha_2021_111429 crossref_primary_10_1039_C9SC01410A crossref_primary_10_1016_j_jtho_2019_07_031 crossref_primary_10_1089_dna_2021_0145 crossref_primary_10_3934_mbe_2022013 crossref_primary_10_1016_j_ctarc_2021_100412 crossref_primary_10_1016_j_imbio_2019_09_007 crossref_primary_10_1186_s43046_024_00236_0 crossref_primary_10_2174_2211738508666200421113215 crossref_primary_10_3934_mbe_2021165 crossref_primary_10_1016_j_colsurfb_2020_111340 crossref_primary_10_1002_jgm_3147 crossref_primary_10_1177_03946320221130727 crossref_primary_10_3390_ijms24032433 crossref_primary_10_1038_s41419_021_03835_0 crossref_primary_10_1183_13993003_00455_2022 crossref_primary_10_2174_0115680096345676241001081051 crossref_primary_10_1002_jbt_70015 crossref_primary_10_1038_s41401_021_00691_8 crossref_primary_10_1293_tox_2022_0040 crossref_primary_10_1186_s12943_023_01791_1 crossref_primary_10_1007_s13187_022_02158_8 crossref_primary_10_3390_ijms252211954 crossref_primary_10_18632_aging_205159 crossref_primary_10_3390_ph17091133 crossref_primary_10_3389_fgene_2022_1005896 crossref_primary_10_1021_acs_molpharmaceut_4c00848 crossref_primary_10_1080_03639045_2025_2484326 crossref_primary_10_1097_MD_0000000000037041 crossref_primary_10_3389_fgene_2022_1037011 crossref_primary_10_1177_1758834017704329 crossref_primary_10_2174_0929867326666190712140545 crossref_primary_10_1016_j_bbcan_2021_188629 crossref_primary_10_1111_1759_7714_13082 crossref_primary_10_2147_CMAR_S370961 crossref_primary_10_3389_fnut_2023_1143213 crossref_primary_10_1016_j_ygeno_2020_12_010 crossref_primary_10_1080_01635581_2020_1801774 crossref_primary_10_1177_0300060519893867 crossref_primary_10_1016_j_rmcr_2020_101258 crossref_primary_10_1038_s41598_017_08257_7 crossref_primary_10_1016_j_jff_2023_105588 crossref_primary_10_1002_iub_2152 crossref_primary_10_1111_1759_7714_13079 crossref_primary_10_1097_CEJ_0000000000000766 crossref_primary_10_1159_000495460 crossref_primary_10_1007_s10528_023_10641_0 crossref_primary_10_1007_s12672_025_01986_6 crossref_primary_10_3390_jcm8040529 crossref_primary_10_3892_ol_2022_13372 crossref_primary_10_1080_14740338_2023_2245324 crossref_primary_10_3390_cancers12102738 crossref_primary_10_3389_fcell_2022_1004429 crossref_primary_10_1186_s12885_023_10535_9 crossref_primary_10_1007_s12026_021_09174_8 crossref_primary_10_53730_ijhs_v7nS1_15345 crossref_primary_10_1016_j_yexcr_2020_111884 crossref_primary_10_1186_s13046_021_01979_7 crossref_primary_10_1038_s41598_023_33404_8 crossref_primary_10_1016_j_intimp_2020_106856 crossref_primary_10_1016_j_jcou_2021_101486 crossref_primary_10_1021_acs_jnatprod_2c00979 crossref_primary_10_1186_s12859_020_3524_8 crossref_primary_10_1111_cpr_13703 crossref_primary_10_1155_2021_8175003 crossref_primary_10_3892_mmr_2019_10644 crossref_primary_10_1074_jbc_RA120_014976 crossref_primary_10_3390_diagnostics12112644 crossref_primary_10_1093_toxres_tfad015 crossref_primary_10_1615_CritRevOncog_2023050439 crossref_primary_10_1016_j_biopha_2020_111111 crossref_primary_10_3892_ijo_2024_5711 crossref_primary_10_1016_j_jtho_2018_12_021 crossref_primary_10_1016_j_cpet_2019_10_001 crossref_primary_10_2147_PGPM_S357166 crossref_primary_10_3389_fonc_2020_01256 crossref_primary_10_3390_ijms24021721 crossref_primary_10_1186_s12906_019_2795_y crossref_primary_10_3892_ijo_2024_5714 crossref_primary_10_1038_s41419_023_06240_x crossref_primary_10_1007_s00262_023_03560_x crossref_primary_10_2147_CMAR_S265671 crossref_primary_10_15252_emmm_201809856 crossref_primary_10_1111_1759_7714_13072 crossref_primary_10_3389_fonc_2022_832517 crossref_primary_10_1097_MD_0000000000028500 crossref_primary_10_3892_mmr_2021_12485 crossref_primary_10_1016_j_lungcan_2021_09_001 crossref_primary_10_2174_0118715206290110240326071909 crossref_primary_10_1016_j_taap_2025_117298 crossref_primary_10_1007_s11033_023_09079_9 crossref_primary_10_2147_OTT_S351085 crossref_primary_10_4236_jbm_2023_1110020 crossref_primary_10_3390_ijerph20085522 crossref_primary_10_1158_0008_5472_CAN_17_1569 crossref_primary_10_1002_mc_23547 crossref_primary_10_1186_s10020_022_00505_5 crossref_primary_10_1186_s40164_021_00211_8 crossref_primary_10_1080_00914037_2022_2163639 crossref_primary_10_1007_s12033_022_00495_z crossref_primary_10_1007_s11684_024_1107_1 crossref_primary_10_1111_1759_7714_14375 crossref_primary_10_1038_s41598_022_12301_6 crossref_primary_10_1245_s10434_021_10982_3 crossref_primary_10_1038_s41417_024_00813_4 crossref_primary_10_3389_fgene_2023_1249678 crossref_primary_10_3389_fimmu_2020_02168 crossref_primary_10_1080_07853890_2021_1925736 crossref_primary_10_1021_acsomega_2c03325 crossref_primary_10_1007_s10735_020_09919_z crossref_primary_10_1016_j_yexmp_2019_104285 crossref_primary_10_1111_jcmm_16340 crossref_primary_10_3389_fphar_2022_895744 crossref_primary_10_1016_j_jep_2021_114514 crossref_primary_10_1088_1361_6528_ac0e68 crossref_primary_10_3390_ijms21134569 crossref_primary_10_3390_jpm14050446 crossref_primary_10_3389_fphar_2025_1540636 crossref_primary_10_1016_j_ejmech_2018_03_051 crossref_primary_10_1002_mco2_483 crossref_primary_10_1038_s41467_022_33210_2 crossref_primary_10_1038_s41598_024_68256_3 crossref_primary_10_3389_fimmu_2022_749241 crossref_primary_10_1080_13880209_2020_1822420 crossref_primary_10_1155_2021_9142364 crossref_primary_10_1371_journal_pone_0259091 crossref_primary_10_3389_fmed_2022_853941 crossref_primary_10_1111_1759_7714_13051 crossref_primary_10_1016_j_phymed_2021_153821 crossref_primary_10_3892_ol_2023_14098 crossref_primary_10_1093_carcin_bgaa094 crossref_primary_10_1142_S0192415X20500974 crossref_primary_10_1016_j_lfs_2021_119042 crossref_primary_10_1371_journal_pone_0226196 crossref_primary_10_1016_j_ijheh_2021_113793 crossref_primary_10_1038_s41571_022_00718_x crossref_primary_10_1007_s00595_018_1659_2 crossref_primary_10_1080_26895293_2022_2025914 crossref_primary_10_1245_s10434_021_11192_7 crossref_primary_10_1186_s12967_019_1931_2 crossref_primary_10_1016_j_cellsig_2025_111590 crossref_primary_10_46237_amusbfd_1287877 crossref_primary_10_1016_j_cbi_2023_110795 crossref_primary_10_1016_j_xjon_2021_08_036 crossref_primary_10_18632_aging_204244 crossref_primary_10_7717_peerj_17816 crossref_primary_10_1007_s12032_022_01755_3 crossref_primary_10_1007_s12247_021_09582_1 crossref_primary_10_1016_j_actbio_2021_01_023 crossref_primary_10_1021_acs_chemrestox_6b00372 crossref_primary_10_3389_fphar_2022_915822 crossref_primary_10_3892_ol_2021_13114 crossref_primary_10_1016_j_biopha_2020_110217 crossref_primary_10_1007_s00432_022_04225_5 crossref_primary_10_3389_fonc_2021_672687 crossref_primary_10_62675_2965_2774_20240054_en crossref_primary_10_1111_his_13346 crossref_primary_10_7326_L19_0065 crossref_primary_10_2147_CMAR_S258497 crossref_primary_10_1177_09720634241276076 crossref_primary_10_1016_j_bbrc_2020_09_047 crossref_primary_10_1016_j_cytogfr_2023_11_003 crossref_primary_10_3389_fgene_2022_817552 crossref_primary_10_32604_or_2024_045025 crossref_primary_10_1038_s41388_021_01696_7 crossref_primary_10_1002_jcp_29564 crossref_primary_10_1016_j_bbrep_2024_101693 crossref_primary_10_1007_s12094_023_03281_8 crossref_primary_10_1038_s41467_020_20527_z crossref_primary_10_1038_s41416_020_0899_2 crossref_primary_10_1016_j_ejphar_2024_176805 crossref_primary_10_18632_aging_206086 crossref_primary_10_3390_dna5010007 crossref_primary_10_3892_ol_2019_11075 crossref_primary_10_1007_s11136_020_02509_2 crossref_primary_10_1080_07357907_2019_1656730 crossref_primary_10_3389_fpubh_2024_1420933 crossref_primary_10_1016_j_jtocrr_2023_100601 crossref_primary_10_3390_ijms24129848 crossref_primary_10_61958_NCDZ9945 crossref_primary_10_1016_j_ijpt_2024_100016 crossref_primary_10_1080_08820139_2022_2130075 crossref_primary_10_1111_jcmm_18577 crossref_primary_10_1186_s12920_024_01863_1 crossref_primary_10_1038_s41598_019_50528_y crossref_primary_10_1111_1759_7714_13912 crossref_primary_10_1016_j_phymed_2022_154109 crossref_primary_10_1007_s00520_018_4167_4 crossref_primary_10_1016_j_jncc_2023_08_004 crossref_primary_10_1007_s12094_022_02792_0 crossref_primary_10_1016_j_lungcan_2020_12_004 crossref_primary_10_1111_ajco_13550 crossref_primary_10_1016_j_drup_2022_100904 crossref_primary_10_1016_j_jtho_2019_05_036 crossref_primary_10_1186_s12885_023_11692_7 crossref_primary_10_1200_GO_21_00046 crossref_primary_10_1016_j_greeac_2024_100177 crossref_primary_10_1089_lap_2024_0164 crossref_primary_10_1038_s43018_021_00236_2 crossref_primary_10_1016_j_ctarc_2021_100462 crossref_primary_10_1089_cbr_2019_3334 crossref_primary_10_1093_neuonc_noac009 crossref_primary_10_1186_s12935_021_01849_4 crossref_primary_10_1186_s13046_025_03345_3 crossref_primary_10_3389_fonc_2022_1022097 crossref_primary_10_3892_ol_2021_13155 crossref_primary_10_1002_cam4_2900 crossref_primary_10_1016_j_prp_2024_155316 crossref_primary_10_3389_fphar_2021_712181 crossref_primary_10_3390_cancers12123668 crossref_primary_10_3389_fmed_2022_843749 crossref_primary_10_1038_s41401_020_0492_5 crossref_primary_10_1093_bib_bbac021 crossref_primary_10_1016_j_prp_2024_155792 crossref_primary_10_1002_ddr_22022 crossref_primary_10_1007_s11427_021_1966_4 crossref_primary_10_3389_fcell_2021_645482 crossref_primary_10_1038_s41419_022_05150_8 crossref_primary_10_1016_j_bbrc_2023_05_001 crossref_primary_10_1007_s00262_024_03837_9 crossref_primary_10_1183_16000617_0122_2021 crossref_primary_10_1016_j_phymed_2022_154118 crossref_primary_10_1038_s41598_024_58539_0 crossref_primary_10_1016_j_colsurfb_2024_114371 crossref_primary_10_1186_s12920_022_01164_5 crossref_primary_10_3389_fphar_2021_728937 crossref_primary_10_1093_carcin_bgae034 crossref_primary_10_1111_1759_7714_13904 crossref_primary_10_1002_ijc_35276 crossref_primary_10_1097_CAD_0000000000001582 crossref_primary_10_1007_s11912_018_0720_z crossref_primary_10_1186_s12885_020_07473_1 crossref_primary_10_1080_21655979_2022_2043099 crossref_primary_10_1038_s41598_021_82892_z crossref_primary_10_20862_0042_4676_2024_105_1_29_36 crossref_primary_10_12998_wjcc_v11_i23_5504 crossref_primary_10_1111_febs_16683 crossref_primary_10_1016_j_prp_2023_155016 crossref_primary_10_3892_ol_2023_14006 crossref_primary_10_3389_fendo_2022_829175 crossref_primary_10_3389_fpsyg_2024_1417668 crossref_primary_10_3390_molecules27217466 crossref_primary_10_1080_17501911_2024_2430166 crossref_primary_10_1186_s13014_021_01889_0 crossref_primary_10_1177_09636897231193066 crossref_primary_10_1080_10799893_2021_2019274 crossref_primary_10_1016_j_prp_2019_02_017 crossref_primary_10_1016_j_phrs_2020_105007 crossref_primary_10_3389_fonc_2021_680287 crossref_primary_10_1155_2022_6567916 crossref_primary_10_3390_cancers11101470 crossref_primary_10_1016_j_pharmthera_2018_09_004 crossref_primary_10_1007_s13273_024_00500_3 crossref_primary_10_1097_CM9_0000000000003117 crossref_primary_10_3389_fonc_2021_671341 crossref_primary_10_1177_0960327120979032 crossref_primary_10_3390_cancers13236050 crossref_primary_10_3389_fgene_2022_768971 crossref_primary_10_1158_1078_0432_CCR_18_1894 crossref_primary_10_1016_j_canlet_2022_215958 crossref_primary_10_3389_fonc_2023_1293441 crossref_primary_10_1016_j_nano_2023_102660 crossref_primary_10_1038_s41419_019_1519_z crossref_primary_10_1186_s12935_021_02267_2 crossref_primary_10_3389_fonc_2021_651915 crossref_primary_10_1002_path_5280 crossref_primary_10_1016_j_yexcr_2021_112661 crossref_primary_10_1038_s41388_025_03296_1 crossref_primary_10_51335_organoid_2021_1_e6 crossref_primary_10_1111_1759_7714_13654 crossref_primary_10_1016_j_omto_2022_10_012 crossref_primary_10_1016_j_prp_2021_153680 crossref_primary_10_1111_1759_7714_13671 crossref_primary_10_3389_fgene_2022_919857 crossref_primary_10_1016_j_lfs_2023_121560 crossref_primary_10_1016_j_omtn_2018_08_020 crossref_primary_10_3390_jcm10204675 crossref_primary_10_2147_IJGM_S338890 crossref_primary_10_1007_s12312_019_00673_2 crossref_primary_10_3390_jcm12134307 crossref_primary_10_1002_tox_24026 crossref_primary_10_2174_2211738511666230525151106 crossref_primary_10_1007_s00262_024_03937_6 crossref_primary_10_1016_j_lungcan_2021_05_011 crossref_primary_10_2217_bmm_2020_0405 crossref_primary_10_3389_fimmu_2022_906420 crossref_primary_10_3389_fonc_2021_669684 crossref_primary_10_1177_0272989X21998951 crossref_primary_10_1051_e3sconf_202124503057 crossref_primary_10_1513_AnnalsATS_201702_167WS crossref_primary_10_1002_jccs_201900435 crossref_primary_10_1002_1878_0261_12204 crossref_primary_10_1111_1759_7714_13664 crossref_primary_10_3390_md21120607 crossref_primary_10_1007_s00280_021_04265_7 crossref_primary_10_1080_21655979_2021_1982274 crossref_primary_10_1016_j_semcancer_2020_02_009 crossref_primary_10_1371_journal_pone_0244382 crossref_primary_10_4103_JOAPM_JOAPM_9_24 crossref_primary_10_3389_fgene_2021_622233 crossref_primary_10_1007_s11095_018_2370_0 crossref_primary_10_1186_s12885_023_10509_x crossref_primary_10_3389_fcell_2021_756911 crossref_primary_10_1186_s12906_019_2601_x crossref_primary_10_1038_s41416_023_02553_y crossref_primary_10_1016_j_heliyon_2024_e34784 crossref_primary_10_1042_BSR20190701 crossref_primary_10_5301_ijbm_5000275 crossref_primary_10_3390_jcm9061790 crossref_primary_10_1002_jcla_23625 crossref_primary_10_1007_s13402_023_00873_y crossref_primary_10_1159_000510103 crossref_primary_10_1155_2021_8856326 crossref_primary_10_1080_14789450_2017_1304215 crossref_primary_10_1016_j_ejrad_2021_109874 crossref_primary_10_1186_s13062_024_00512_y crossref_primary_10_1016_j_molstruc_2024_140295 crossref_primary_10_2174_0929867326666190222183219 crossref_primary_10_1016_j_compbiomed_2020_104141 crossref_primary_10_1186_s12964_022_00825_3 crossref_primary_10_1002_cbin_11454 crossref_primary_10_1186_s40364_023_00484_7 crossref_primary_10_1200_PO_20_00516 crossref_primary_10_1515_dmpt_2022_0112 crossref_primary_10_1038_nature25183 crossref_primary_10_1186_s12935_021_02027_2 crossref_primary_10_1016_j_jbc_2024_107783 crossref_primary_10_1002_cam4_6309 crossref_primary_10_1053_j_ro_2023_02_001 crossref_primary_10_1038_s41598_023_38350_z crossref_primary_10_3892_etm_2023_12239 crossref_primary_10_1038_s41598_022_12862_6 crossref_primary_10_1080_15384101_2024_2305535 crossref_primary_10_1166_jbt_2021_2700 crossref_primary_10_3389_fonc_2022_1013544 crossref_primary_10_1016_j_bioorg_2024_107648 crossref_primary_10_1007_s00595_024_02987_8 crossref_primary_10_1002_cam4_5451 crossref_primary_10_1155_2021_5582648 crossref_primary_10_1097_eus_0000000000000051 crossref_primary_10_3389_fgene_2022_905650 crossref_primary_10_1016_j_intimp_2020_107134 crossref_primary_10_1371_journal_pone_0295966 crossref_primary_10_1016_j_cllc_2021_03_014 crossref_primary_10_1038_s41389_020_0241_0 crossref_primary_10_1007_s13577_022_00752_y crossref_primary_10_1007_s11033_022_08023_7 crossref_primary_10_1002_jcp_31426 crossref_primary_10_3390_jcm12041429 crossref_primary_10_1016_j_jacbts_2016_11_010 crossref_primary_10_1007_s12094_020_02503_7 crossref_primary_10_18553_jmcp_2024_30_9_1041 crossref_primary_10_3389_fpubh_2022_1060798 crossref_primary_10_1001_jamanetworkopen_2022_52885 crossref_primary_10_2147_OTT_S273797 crossref_primary_10_1007_s00432_020_03189_8 crossref_primary_10_3892_ijmm_2019_4197 crossref_primary_10_1016_j_yexcr_2024_114010 crossref_primary_10_3389_fonc_2019_00306 crossref_primary_10_1177_1934578X221120215 crossref_primary_10_1016_j_lungcan_2019_01_006 crossref_primary_10_1111_jcmm_14844 crossref_primary_10_1186_s12943_023_01740_y crossref_primary_10_18632_aging_103502 crossref_primary_10_3390_cells8080840 crossref_primary_10_3390_cells12071002 crossref_primary_10_1016_j_bbrc_2019_03_198 crossref_primary_10_1186_s12885_021_07959_6 crossref_primary_10_3389_fgene_2022_894024 crossref_primary_10_1016_j_wneu_2023_09_021 crossref_primary_10_1016_j_ygeno_2020_02_012 crossref_primary_10_1111_crj_12906 crossref_primary_10_1016_j_heliyon_2024_e38702 crossref_primary_10_1002_kjm2_12673 crossref_primary_10_3389_fmed_2020_00090 crossref_primary_10_1186_s12890_022_02267_6 crossref_primary_10_34175_jno202002004 crossref_primary_10_2139_ssrn_4184813 crossref_primary_10_2217_fon_2019_0812 crossref_primary_10_1080_01902148_2021_1916651 crossref_primary_10_1111_1759_7714_14938 crossref_primary_10_3390_jcm12041442 crossref_primary_10_1038_s41598_021_88209_4 crossref_primary_10_1016_j_drup_2024_101154 crossref_primary_10_2147_CMAR_S270790 crossref_primary_10_3389_fphar_2020_578091 crossref_primary_10_3389_fonc_2023_1104137 crossref_primary_10_1111_1759_7714_14110 crossref_primary_10_1002_ijc_31545 crossref_primary_10_1089_crispr_2022_0070 crossref_primary_10_1016_j_biopha_2024_116445 crossref_primary_10_3390_biom9080361 crossref_primary_10_1002_cam4_5410 crossref_primary_10_1016_j_arabjc_2023_105011 crossref_primary_10_2147_CMAR_S320965 crossref_primary_10_1021_acs_jmedchem_1c00649 crossref_primary_10_3389_fonc_2021_642110 crossref_primary_10_1016_j_cca_2019_11_031 crossref_primary_10_1053_j_jvca_2022_04_028 crossref_primary_10_2147_IJGM_S338019 crossref_primary_10_1111_1759_7714_13274 crossref_primary_10_3390_ijerph182211827 crossref_primary_10_1053_j_semnuclmed_2022_04_007 crossref_primary_10_1111_1759_7714_13271 crossref_primary_10_1038_s41419_025_07505_3 crossref_primary_10_1007_s12033_021_00443_3 crossref_primary_10_1007_s12094_023_03255_w crossref_primary_10_2147_OTT_S244339 crossref_primary_10_1007_s11655_024_4116_7 crossref_primary_10_1016_j_canlet_2021_12_022 crossref_primary_10_1017_S0007114522003865 crossref_primary_10_1186_s12885_021_09108_5 crossref_primary_10_1186_s40364_022_00441_w crossref_primary_10_1016_j_heliyon_2024_e33888 crossref_primary_10_1016_j_biopha_2022_112771 crossref_primary_10_3389_fonc_2021_743050 crossref_primary_10_1016_j_intimp_2022_108652 crossref_primary_10_1038_s41598_019_39965_x crossref_primary_10_1080_17476348_2019_1623027 crossref_primary_10_1111_1759_7714_14597 crossref_primary_10_1080_17460441_2020_1791080 crossref_primary_10_1007_s10552_022_01579_6 crossref_primary_10_1080_03007995_2022_2129231 crossref_primary_10_1097_CEJ_0000000000000598 crossref_primary_10_2174_1871520622666221010092922 crossref_primary_10_3390_cancers15174344 crossref_primary_10_1007_s40273_021_01073_y crossref_primary_10_1007_s12032_023_02206_3 crossref_primary_10_1097_CM9_0000000000002991 crossref_primary_10_3389_fonc_2021_666589 crossref_primary_10_1016_j_heliyon_2023_e14811 crossref_primary_10_3390_vaccines9020094 crossref_primary_10_3389_fphys_2023_1236651 crossref_primary_10_1016_j_ebiom_2021_103340 crossref_primary_10_3892_ijmm_2021_5055 crossref_primary_10_1016_j_canlet_2019_03_045 crossref_primary_10_3389_fonc_2022_1023776 crossref_primary_10_1016_j_semcancer_2022_03_006 crossref_primary_10_1177_17588359231192396 crossref_primary_10_1002_cam4_5447 crossref_primary_10_1016_j_phymed_2024_156278 crossref_primary_10_1016_j_tiv_2020_104971 crossref_primary_10_1016_j_phrs_2020_104919 crossref_primary_10_3389_fchem_2021_789934 crossref_primary_10_3892_ol_2021_12852 crossref_primary_10_1016_j_cbi_2019_108932 crossref_primary_10_3390_pharmaceutics16010083 crossref_primary_10_1186_s12885_024_12573_3 crossref_primary_10_1021_acsami_1c16351 crossref_primary_10_3233_CBM_230154 crossref_primary_10_1002_mc_23805 crossref_primary_10_1038_s41419_020_2701_z crossref_primary_10_1186_s12935_023_03204_1 crossref_primary_10_3389_fphar_2025_1511171 crossref_primary_10_18632_oncotarget_18640 crossref_primary_10_1038_s41419_022_04655_6 crossref_primary_10_1186_s13256_021_02748_y crossref_primary_10_1620_tjem_248_3 crossref_primary_10_1016_j_canlet_2023_216205 crossref_primary_10_1016_j_critrevonc_2023_104195 crossref_primary_10_1534_g3_120_401207 crossref_primary_10_1007_s11427_022_2230_4 crossref_primary_10_1016_j_yexmp_2019_04_001 crossref_primary_10_1021_acsami_1c04305 crossref_primary_10_1038_s41598_024_62825_2 crossref_primary_10_1186_s12885_022_09885_7 crossref_primary_10_3389_fphar_2021_801580 crossref_primary_10_1038_s41401_020_0443_1 crossref_primary_10_3390_antiox9100961 crossref_primary_10_3390_healthcare11222920 crossref_primary_10_1186_s11658_019_0198_1 crossref_primary_10_2147_DDDT_S489234 crossref_primary_10_3389_fphar_2022_834317 crossref_primary_10_1111_cas_15668 crossref_primary_10_1080_0284186X_2023_2218040 crossref_primary_10_62347_QHFA9669 crossref_primary_10_1016_j_biopha_2022_112735 crossref_primary_10_2174_1381612828666220727144223 crossref_primary_10_3390_cancers11060888 crossref_primary_10_1016_j_molstruc_2022_134619 crossref_primary_10_3389_fphar_2024_1507194 crossref_primary_10_1016_j_tice_2022_101974 crossref_primary_10_3390_genes9010016 crossref_primary_10_1016_j_actbio_2020_03_004 crossref_primary_10_1097_MD_0000000000025415 crossref_primary_10_1155_2022_3045370 crossref_primary_10_2478_fco_2019_0014 crossref_primary_10_1007_s12010_024_04973_9 crossref_primary_10_1186_s12885_023_11512_y crossref_primary_10_1039_D2QI01383E crossref_primary_10_1371_journal_pone_0251080 crossref_primary_10_1016_j_omto_2022_02_016 crossref_primary_10_3389_fphar_2024_1378483 crossref_primary_10_3389_fimmu_2024_1491872 crossref_primary_10_2174_1566524023666230619123752 crossref_primary_10_1007_s00432_019_03051_6 crossref_primary_10_3390_cancers15184445 crossref_primary_10_1016_j_intimp_2024_112495 crossref_primary_10_1097_CCO_0000000000000913 crossref_primary_10_18632_aging_203318 crossref_primary_10_7717_peerj_17143 crossref_primary_10_1016_j_ajpath_2021_11_006 crossref_primary_10_1136_jitc_2022_005902 crossref_primary_10_1016_j_ymthe_2022_06_011 crossref_primary_10_1016_j_ejphar_2021_174550 crossref_primary_10_1186_s13045_023_01439_z crossref_primary_10_1016_j_mcp_2023_101909 crossref_primary_10_62675_2965_2774_20240054_pt crossref_primary_10_1186_s13578_023_01101_8 crossref_primary_10_1016_j_jtcvs_2020_11_108 crossref_primary_10_1016_j_ygeno_2023_110684 crossref_primary_10_1111_1759_7714_13204 crossref_primary_10_2174_187447101303201029121009 crossref_primary_10_3389_fgene_2023_1200262 crossref_primary_10_3892_mmr_2021_12338 crossref_primary_10_1166_jbn_2022_3292 crossref_primary_10_3389_fimmu_2025_1448438 crossref_primary_10_1080_1120009X_2023_2294582 crossref_primary_10_1186_s12885_020_06762_z crossref_primary_10_1016_j_molstruc_2022_132416 crossref_primary_10_3389_fimmu_2020_02024 crossref_primary_10_3892_or_2023_8633 crossref_primary_10_1155_2021_4522210 crossref_primary_10_1016_j_cllc_2017_06_005 crossref_primary_10_1016_j_bmcl_2020_127698 crossref_primary_10_1002_jcb_29675 crossref_primary_10_1016_j_cllc_2017_06_008 crossref_primary_10_1016_j_lfs_2021_119105 crossref_primary_10_1016_j_mri_2024_01_014 crossref_primary_10_1155_2022_3437073 crossref_primary_10_1177_10732748221077351 crossref_primary_10_1007_s00520_018_4222_1 crossref_primary_10_1111_1759_7714_15399 crossref_primary_10_3389_fcell_2022_833579 crossref_primary_10_1038_s41598_023_51108_x crossref_primary_10_1097_MD_0000000000030760 crossref_primary_10_1038_s42003_023_04581_z crossref_primary_10_1186_s12967_019_02173_2 crossref_primary_10_1038_s41598_024_53622_y crossref_primary_10_1016_j_bbrc_2020_10_107 crossref_primary_10_2147_CMAR_S331222 crossref_primary_10_3233_CBM_210189 crossref_primary_10_1016_j_jgg_2023_02_014 crossref_primary_10_1002_ptr_6352 crossref_primary_10_18632_aging_205038 crossref_primary_10_2147_OTT_S241231 crossref_primary_10_1186_s12931_019_0994_1 crossref_primary_10_1186_s12920_022_01413_7 crossref_primary_10_1016_j_bcp_2023_115627 crossref_primary_10_2196_37190 crossref_primary_10_2147_OTT_S401454 crossref_primary_10_1016_j_asjsur_2024_07_092 crossref_primary_10_1186_s12957_022_02706_y crossref_primary_10_7717_peerj_12624 crossref_primary_10_1016_j_biopha_2023_114362 crossref_primary_10_1155_2023_9162249 crossref_primary_10_1016_j_lungcan_2019_03_015 crossref_primary_10_4103_jmau_jmau_89_24 crossref_primary_10_1016_j_intimp_2020_106744 crossref_primary_10_1093_ejcts_ezae335 crossref_primary_10_1111_febs_14977 crossref_primary_10_1177_1934578X231169370 crossref_primary_10_3389_fonc_2022_791916 crossref_primary_10_1002_mco2_325 crossref_primary_10_1016_j_clinimag_2025_110442 crossref_primary_10_2147_IJN_S254774 crossref_primary_10_1002_smtd_202000648 crossref_primary_10_1016_j_phymed_2022_154299 crossref_primary_10_1142_S0219720023500208 crossref_primary_10_2147_OTT_S240399 crossref_primary_10_3390_ijms241713618 crossref_primary_10_3390_ijms24032580 crossref_primary_10_18632_aging_204169 crossref_primary_10_3390_cancers13102290 crossref_primary_10_1111_jebm_12606 crossref_primary_10_1007_s00408_023_00665_z crossref_primary_10_3389_fonc_2020_01141 crossref_primary_10_3389_fphar_2022_1109822 crossref_primary_10_1016_j_lungcan_2020_06_019 crossref_primary_10_1080_14712598_2020_1790522 crossref_primary_10_1016_j_canlet_2022_216021 crossref_primary_10_1177_17588359231210274 crossref_primary_10_3389_fendo_2023_1220108 crossref_primary_10_1016_j_biocel_2020_105825 crossref_primary_10_1089_hgtb_2019_115 crossref_primary_10_1016_j_scr_2021_102630 crossref_primary_10_1007_s10528_025_11030_5 crossref_primary_10_1186_s12885_020_07212_6 crossref_primary_10_1158_1078_0432_CCR_17_1875 crossref_primary_10_3389_fonc_2021_699847 crossref_primary_10_3390_molecules27020473 crossref_primary_10_1038_s41392_020_0149_3 crossref_primary_10_3389_fimmu_2022_1033483 crossref_primary_10_3389_fphar_2022_940704 crossref_primary_10_2147_CMAR_S253327 crossref_primary_10_3389_fonc_2022_790645 crossref_primary_10_1016_j_lungcan_2021_10_007 crossref_primary_10_18632_aging_205464 crossref_primary_10_15252_emmm_201809976 crossref_primary_10_1038_s41598_023_50163_8 crossref_primary_10_1016_j_arcmed_2020_08_004 crossref_primary_10_1007_s11523_022_00937_3 crossref_primary_10_1016_j_canlet_2022_215585 crossref_primary_10_1016_j_ijpharm_2023_123728 crossref_primary_10_3390_chemistry6040040 crossref_primary_10_1016_j_msec_2019_109739 crossref_primary_10_1183_23120541_00040_2018 crossref_primary_10_1136_jitc_2020_000946 crossref_primary_10_1080_02656736_2019_1683234 crossref_primary_10_54097_hset_v8i_1119 crossref_primary_10_1038_s41418_020_00616_8 crossref_primary_10_54097_hset_v8i_1115 crossref_primary_10_1136_thoraxjnl_2021_218183 crossref_primary_10_3389_fgene_2023_1092968 crossref_primary_10_1515_med_2021_0321 crossref_primary_10_3389_fonc_2022_786124 crossref_primary_10_1007_s12672_025_01854_3 crossref_primary_10_1002_ijc_34238 crossref_primary_10_1515_biol_2020_0035 crossref_primary_10_3390_cancers14143550 crossref_primary_10_1002_ijc_33381 crossref_primary_10_1177_1533033820934129 crossref_primary_10_1515_med_2022_0538 crossref_primary_10_1007_s00408_024_00709_y crossref_primary_10_1158_1055_9965_EPI_19_0221 crossref_primary_10_2217_fon_2019_0393 crossref_primary_10_1007_s00432_023_04790_3 crossref_primary_10_1080_14789450_2017_1392245 crossref_primary_10_1007_s43441_021_00345_1 crossref_primary_10_1186_s12967_019_2068_z crossref_primary_10_1021_acsomega_3c09667 crossref_primary_10_1002_1878_0261_13168 crossref_primary_10_1002_1878_0261_13167 crossref_primary_10_3892_ol_2020_11508 crossref_primary_10_1002_adma_202415818 crossref_primary_10_1097_CEJ_0000000000000684 crossref_primary_10_1186_s12890_021_01796_w crossref_primary_10_1155_2022_1112987 crossref_primary_10_1016_j_biopha_2020_110371 crossref_primary_10_1159_000531986 crossref_primary_10_1016_j_bbadis_2025_167709 crossref_primary_10_1007_s12672_022_00489_y crossref_primary_10_1016_j_pharmthera_2023_108347 crossref_primary_10_1080_07853890_2024_2430029 crossref_primary_10_3390_cells12020273 crossref_primary_10_1007_s13755_023_00263_6 crossref_primary_10_1177_15353702231184223 crossref_primary_10_18632_aging_102670 crossref_primary_10_1080_14737140_2021_1924683 crossref_primary_10_3892_ijo_2019_4805 crossref_primary_10_3389_fphar_2023_1242488 crossref_primary_10_1080_21655979_2021_1976896 crossref_primary_10_1172_jci_insight_152815 crossref_primary_10_3389_fimmu_2023_1098700 crossref_primary_10_3390_ph16071042 crossref_primary_10_1038_s41419_021_03601_2 crossref_primary_10_1038_s41598_022_20730_6 crossref_primary_10_1039_C9BM00812H crossref_primary_10_3892_ijo_2019_4808 crossref_primary_10_1186_s13014_023_02243_2 crossref_primary_10_1016_j_bbrc_2021_03_137 crossref_primary_10_2217_fon_2017_0405 crossref_primary_10_1038_s41598_019_45977_4 crossref_primary_10_1002_cbin_11868 crossref_primary_10_3390_cancers12113371 crossref_primary_10_2196_25576 crossref_primary_10_1002_cam4_7283 crossref_primary_10_1016_j_cca_2022_06_009 crossref_primary_10_23736_S0031_0808_20_03978_6 crossref_primary_10_3389_fsurg_2021_753801 crossref_primary_10_1007_s11356_023_26307_8 crossref_primary_10_3390_ijms232214294 crossref_primary_10_1016_j_jtcvs_2019_08_138 crossref_primary_10_1172_JCI164413 crossref_primary_10_1016_j_neunet_2022_04_027 crossref_primary_10_2147_IJN_S390984 crossref_primary_10_1016_j_jep_2023_117232 crossref_primary_10_1016_j_lungcan_2024_107894 crossref_primary_10_1089_cbr_2019_3228 crossref_primary_10_1080_15384101_2021_2024997 crossref_primary_10_1021_acsami_4c21740 crossref_primary_10_1155_2022_9111681 crossref_primary_10_1186_s13690_021_00588_2 crossref_primary_10_1016_j_cca_2018_09_027 crossref_primary_10_1016_j_cellimm_2020_104211 crossref_primary_10_3390_cancers13164037 crossref_primary_10_1093_hmg_ddad208 crossref_primary_10_1007_s12192_019_01063_2 crossref_primary_10_1177_2050312120918996 crossref_primary_10_1038_s41392_023_01706_y crossref_primary_10_3390_ijms26020583 crossref_primary_10_1016_j_actbio_2024_07_033 crossref_primary_10_3389_fonc_2023_1180723 crossref_primary_10_1016_j_intimp_2024_113811 crossref_primary_10_31083_j_fbl2909314 crossref_primary_10_7717_peerj_9086 crossref_primary_10_1021_acsanm_3c00389 crossref_primary_10_1038_s41598_023_27544_0 crossref_primary_10_3390_cancers12113333 crossref_primary_10_1016_j_canlet_2021_08_007 crossref_primary_10_1186_s12943_025_02245_6 crossref_primary_10_1016_j_gene_2024_149183 crossref_primary_10_1016_j_bbadis_2023_166670 crossref_primary_10_3390_cells11223678 crossref_primary_10_1016_j_tiv_2024_105801 crossref_primary_10_1016_j_heliyon_2024_e36032 crossref_primary_10_1016_j_pulmoe_2018_07_004 crossref_primary_10_1002_jbio_202300047 crossref_primary_10_3389_fmicb_2022_850444 crossref_primary_10_1038_s42256_020_0173_6 crossref_primary_10_7717_peerj_12275 crossref_primary_10_1038_s41698_024_00584_z crossref_primary_10_3390_cancers14030528 crossref_primary_10_1007_s00432_022_04555_4 crossref_primary_10_1016_j_cllc_2019_07_014 crossref_primary_10_1097_CAD_0000000000001226 crossref_primary_10_1016_j_gendis_2023_101162 crossref_primary_10_1038_s41420_022_01276_y crossref_primary_10_1016_j_lfs_2023_121655 crossref_primary_10_1038_s41598_021_83668_1 crossref_primary_10_3390_cancers14194709 crossref_primary_10_1038_s41419_023_06069_4 crossref_primary_10_1007_s12262_020_02084_3 crossref_primary_10_1080_13696998_2023_2272536 crossref_primary_10_1097_PAI_0000000000001039 crossref_primary_10_3389_fonc_2022_1003230 crossref_primary_10_3389_fpubh_2021_622154 crossref_primary_10_1002_jcp_27423 crossref_primary_10_1039_D0TB01053G crossref_primary_10_1186_s12957_024_03639_4 crossref_primary_10_1002_mc_23038 crossref_primary_10_1002_ptr_6704 crossref_primary_10_1158_1541_7786_MCR_21_1000 crossref_primary_10_3390_cancers12123574 crossref_primary_10_3390_genes13122295 crossref_primary_10_1016_j_omtn_2019_09_028 crossref_primary_10_1038_s41571_023_00745_2 crossref_primary_10_1038_s41388_021_02054_3 crossref_primary_10_3390_cancers12123579 crossref_primary_10_1016_j_cpt_2022_12_004 crossref_primary_10_1016_j_cllc_2017_04_001 crossref_primary_10_1007_s00432_020_03244_4 crossref_primary_10_3390_cancers15215229 crossref_primary_10_3390_ijms22020593 crossref_primary_10_1097_MD_0000000000019533 crossref_primary_10_1089_cbr_2019_3258 crossref_primary_10_1002_cam4_5081 crossref_primary_10_1007_s12253_020_00844_w crossref_primary_10_2147_PGPM_S403868 crossref_primary_10_1186_s12964_021_00818_8 crossref_primary_10_1038_s41698_023_00434_4 crossref_primary_10_1016_j_ymthe_2021_05_014 crossref_primary_10_3389_fimmu_2024_1359302 crossref_primary_10_1186_s12906_023_04221_3 crossref_primary_10_1038_s41401_022_00890_x crossref_primary_10_1016_j_compbiomed_2022_105701 crossref_primary_10_55971_EJLS_1267898 crossref_primary_10_1038_s41598_022_25050_3 crossref_primary_10_52547_ibj_3732 crossref_primary_10_1177_10732748241247170 crossref_primary_10_1097_MD_0000000000034201 crossref_primary_10_1080_10408444_2020_1763252 crossref_primary_10_3727_096504020X15929939001042 crossref_primary_10_2147_DDDT_S311107 crossref_primary_10_1002_jcp_30250 crossref_primary_10_1109_TMI_2021_3097665 crossref_primary_10_3389_fphar_2021_732716 crossref_primary_10_1007_s13402_023_00896_5 crossref_primary_10_1038_s41420_024_02251_5 crossref_primary_10_1016_j_biopha_2019_109049 crossref_primary_10_1021_acs_analchem_4c05038 crossref_primary_10_1038_s41388_020_01528_0 crossref_primary_10_1038_s41419_020_02900_4 crossref_primary_10_18632_aging_205838 crossref_primary_10_18632_aging_205837 crossref_primary_10_2147_PGPM_S424326 crossref_primary_10_2174_1566524022666211222155118 crossref_primary_10_1016_j_ctarc_2023_100767 crossref_primary_10_4103_jmedsci_jmedsci_384_20 crossref_primary_10_1155_2021_9549287 crossref_primary_10_1002_cncy_22644 crossref_primary_10_1186_s12885_021_08462_8 crossref_primary_10_1016_j_nanoen_2024_109514 crossref_primary_10_3389_fgene_2022_905581 crossref_primary_10_1371_journal_pone_0316432 crossref_primary_10_1111_cyt_12743 crossref_primary_10_1016_j_jinorgbio_2022_111865 crossref_primary_10_1016_j_molimm_2022_12_008 crossref_primary_10_1007_s44197_023_00144_x crossref_primary_10_1016_j_apsusc_2022_156257 crossref_primary_10_20960_revmedlab_00175 crossref_primary_10_1039_D4TB00009A crossref_primary_10_1136_bcr_2021_247530 crossref_primary_10_3892_mmr_2020_11492 crossref_primary_10_1186_s12967_020_02606_3 crossref_primary_10_3164_jcbn_22_122 crossref_primary_10_1016_j_ijbiomac_2024_138211 crossref_primary_10_1136_jitc_2021_003733 crossref_primary_10_3390_brainsci12111486 crossref_primary_10_7717_peerj_8299 crossref_primary_10_1186_s12964_023_01401_z crossref_primary_10_1016_j_jtho_2018_08_2020 crossref_primary_10_1016_j_lungcan_2024_107936 crossref_primary_10_1080_21655979_2021_1971029 crossref_primary_10_2174_0109298673273414231101082153 crossref_primary_10_1016_j_bcp_2024_116207 crossref_primary_10_1186_s41065_024_00328_w crossref_primary_10_1016_j_phrs_2023_106656 crossref_primary_10_3389_fphar_2022_806995 crossref_primary_10_1016_j_biopha_2019_109023 crossref_primary_10_1186_s12967_024_05112_y crossref_primary_10_1038_s41420_021_00651_5 crossref_primary_10_1016_j_cyto_2023_156376 crossref_primary_10_1016_j_ijpharm_2022_121622 crossref_primary_10_3390_cryst11010024 crossref_primary_10_1038_s41417_022_00572_0 crossref_primary_10_3390_cancers12113192 crossref_primary_10_2174_1389201024666230417091625 crossref_primary_10_3892_or_2024_8808 crossref_primary_10_1158_0008_5472_CAN_19_1019 crossref_primary_10_1186_s12967_021_03031_w crossref_primary_10_1016_j_ijbiomac_2025_139823 crossref_primary_10_7717_peerj_8288 crossref_primary_10_1111_1759_7714_14614 crossref_primary_10_1007_s00432_021_03731_2 crossref_primary_10_1080_10837450_2023_2206668 crossref_primary_10_1016_j_ejrad_2021_109988 crossref_primary_10_1186_s40659_024_00551_9 crossref_primary_10_1111_ajco_13343 crossref_primary_10_3390_cancers12123822 crossref_primary_10_12677_ACM_2021_114217 crossref_primary_10_1172_jci_insight_131596 crossref_primary_10_1016_j_lfs_2018_12_052 crossref_primary_10_1016_j_jvir_2020_06_007 crossref_primary_10_1016_j_ctarc_2023_100730 crossref_primary_10_1200_GO_23_00258 crossref_primary_10_31083_j_fbl2803056 crossref_primary_10_1186_s12889_024_18086_9 crossref_primary_10_1186_s12890_020_01180_0 crossref_primary_10_1183_13993003_02072_2017 crossref_primary_10_3389_fonc_2021_640933 crossref_primary_10_5114_aoms_174578 crossref_primary_10_1016_j_biopha_2019_109089 crossref_primary_10_1177_1533033820983086 crossref_primary_10_1016_j_critrevonc_2021_103417 crossref_primary_10_1515_tjb_2024_0225 crossref_primary_10_1097_MD_0000000000021789 crossref_primary_10_1016_j_labinv_2022_100010 crossref_primary_10_1021_acs_jmedchem_4c01133 crossref_primary_10_3389_fimmu_2023_1217590 crossref_primary_10_1590_1980_220x_reeusp_2024_0170en crossref_primary_10_1016_j_biopha_2020_109962 crossref_primary_10_1016_j_lungcan_2020_02_012 crossref_primary_10_3892_br_2017_1034 crossref_primary_10_18632_aging_202761 crossref_primary_10_1007_s44272_025_00029_z crossref_primary_10_3389_fphar_2022_918317 crossref_primary_10_1111_jcmm_16907 crossref_primary_10_1080_21655979_2022_2065946 crossref_primary_10_1038_s41598_025_85471_8 crossref_primary_10_1002_advs_202407575 crossref_primary_10_3389_fimmu_2024_1366096 crossref_primary_10_3390_curroncol29080451 crossref_primary_10_3892_ijo_2022_5443 crossref_primary_10_1109_TCBB_2024_3421924 crossref_primary_10_1080_17476348_2024_2302199 crossref_primary_10_1016_j_arabjc_2022_103721 crossref_primary_10_1080_13880209_2023_2292266 crossref_primary_10_1016_j_heliyon_2023_e14334 crossref_primary_10_1038_s41420_022_01098_y crossref_primary_10_1002_tox_24162 crossref_primary_10_1016_j_biopha_2017_08_003 crossref_primary_10_1002_tox_24161 crossref_primary_10_1016_j_tice_2021_101719 crossref_primary_10_1038_s41598_024_73542_1 crossref_primary_10_1002_cam4_4039 crossref_primary_10_1016_j_ejmech_2018_08_072 crossref_primary_10_3892_ol_2025_14878 crossref_primary_10_3389_fonc_2022_906372 crossref_primary_10_3390_cancers13184637 crossref_primary_10_3390_cancers16172970 crossref_primary_10_1021_acs_jproteome_2c00316 crossref_primary_10_1155_2021_5534823 crossref_primary_10_3389_fonc_2022_862602 crossref_primary_10_1155_2021_5510869 crossref_primary_10_2147_PGPM_S375284 crossref_primary_10_1615_JEnvironPatholToxicolOncol_2022044374 crossref_primary_10_33590_emjoncol_19_00107 crossref_primary_10_3390_cancers14205043 crossref_primary_10_1021_acsanm_5c00088 crossref_primary_10_1097_CAD_0000000000001403 crossref_primary_10_1016_j_molimm_2019_11_008 crossref_primary_10_1016_j_intimp_2021_108260 crossref_primary_10_1038_s41598_025_90537_8 crossref_primary_10_1111_1759_7714_13382 crossref_primary_10_3390_cancers13010112 crossref_primary_10_1002_ddr_21765 crossref_primary_10_1002_jbt_22560 crossref_primary_10_1016_j_canlet_2023_216365 crossref_primary_10_1080_2162402X_2024_2355684 crossref_primary_10_1186_s12957_021_02333_z crossref_primary_10_1080_17512433_2023_2188194 crossref_primary_10_1007_s12598_022_02185_w crossref_primary_10_1093_ejcts_ezae071 crossref_primary_10_1111_1759_7714_13379 crossref_primary_10_1136_bmjopen_2022_070188 crossref_primary_10_1186_s12935_021_02226_x crossref_primary_10_12677_ACM_2023_1391937 crossref_primary_10_18632_aging_202397 crossref_primary_10_3390_jpm12030480 crossref_primary_10_3389_fonc_2024_1428018 crossref_primary_10_3390_cancers15245781 crossref_primary_10_1016_j_omto_2021_02_015 crossref_primary_10_1016_j_ncrna_2024_01_013 crossref_primary_10_3389_fonc_2023_1053248 crossref_primary_10_1039_D1BM00766A crossref_primary_10_1371_journal_pone_0314655 crossref_primary_10_1016_j_addr_2021_114038 crossref_primary_10_1166_sam_2023_4470 crossref_primary_10_1007_s11596_023_2798_2 crossref_primary_10_2196_29017 crossref_primary_10_3389_fmed_2021_663558 crossref_primary_10_1186_s12935_021_02022_7 crossref_primary_10_1016_j_cclet_2025_111032 crossref_primary_10_1002_jcsm_13568 crossref_primary_10_3892_ol_2019_9906 crossref_primary_10_1016_j_heliyon_2024_e24816 crossref_primary_10_1097_PAI_0000000000000818 crossref_primary_10_1177_15330338221133222 crossref_primary_10_3390_cancers14184424 crossref_primary_10_1016_j_biopha_2022_113753 crossref_primary_10_3389_fchem_2023_1124448 crossref_primary_10_1016_j_lfs_2021_119649 crossref_primary_10_2174_1871520619666190307120441 crossref_primary_10_1016_j_envpol_2022_120943 crossref_primary_10_1155_2021_8816860 crossref_primary_10_1038_s41419_019_2075_2 crossref_primary_10_1186_s12890_023_02490_9 crossref_primary_10_1002_cncy_22273 crossref_primary_10_1038_s42003_024_05801_w crossref_primary_10_18632_aging_205880 crossref_primary_10_3389_fimmu_2021_782551 crossref_primary_10_1016_j_esmoop_2021_100095 crossref_primary_10_3233_CBM_220227 crossref_primary_10_1016_j_compbiomed_2024_108174 crossref_primary_10_1186_s12935_022_02592_0 crossref_primary_10_3389_fimmu_2023_1117760 crossref_primary_10_1038_s41401_021_00657_w crossref_primary_10_18632_aging_203235 crossref_primary_10_18632_aging_205418 crossref_primary_10_1186_s12885_023_11548_0 crossref_primary_10_1016_j_heliyon_2024_e27071 crossref_primary_10_1016_j_crad_2023_09_027 crossref_primary_10_1177_15330338231167732 crossref_primary_10_1007_s10637_022_01232_8 crossref_primary_10_1016_j_cclet_2021_03_052 crossref_primary_10_1016_j_biopha_2024_116124 crossref_primary_10_1016_j_csbj_2021_07_007 crossref_primary_10_1055_a_2458_7088 crossref_primary_10_3389_fonc_2022_1101289 crossref_primary_10_3892_ol_2021_12989 crossref_primary_10_18632_aging_202351 crossref_primary_10_1021_acsomega_4c07295 crossref_primary_10_3389_fonc_2020_566511 crossref_primary_10_1016_j_critrevonc_2025_104645 crossref_primary_10_1002_biof_2141 crossref_primary_10_3389_fphar_2021_764331 crossref_primary_10_1016_j_lungcan_2024_107918 crossref_primary_10_1097_MD_0000000000035572 crossref_primary_10_1111_1759_7714_13352 crossref_primary_10_3390_md17060362 crossref_primary_10_1159_000512621 crossref_primary_10_3390_ph17121742 crossref_primary_10_1186_s12885_025_13543_z crossref_primary_10_1186_s12935_021_02368_y crossref_primary_10_1186_s12957_021_02346_8 crossref_primary_10_3390_cancers14184433 crossref_primary_10_3390_ph16060871 crossref_primary_10_1166_jbt_2022_3132 crossref_primary_10_1002_jcb_29525 crossref_primary_10_1016_j_poly_2023_116705 crossref_primary_10_3389_fimmu_2024_1529949 crossref_primary_10_1007_s10637_024_01439_x crossref_primary_10_1038_s41388_020_01474_x crossref_primary_10_1016_j_medmic_2022_100055 crossref_primary_10_1080_14786419_2024_2305660 crossref_primary_10_1016_j_conctc_2019_100445 crossref_primary_10_1016_j_jmoldx_2021_01_004 crossref_primary_10_3892_ol_2019_10795 crossref_primary_10_3892_ol_2019_10796 crossref_primary_10_3389_fonc_2024_1486371 crossref_primary_10_1007_s12094_021_02638_1 crossref_primary_10_1155_2022_9422902 crossref_primary_10_2139_ssrn_3977793 crossref_primary_10_7717_peerj_8654 crossref_primary_10_1007_s13402_019_00459_7 crossref_primary_10_18632_aging_205840 crossref_primary_10_1002_cam4_3570 crossref_primary_10_1016_j_bioorg_2022_106259 crossref_primary_10_3390_cancers14235731 crossref_primary_10_12677_ACM_2023_133596 crossref_primary_10_1186_s12859_022_04869_7 crossref_primary_10_1155_2023_7129325 crossref_primary_10_2174_0929867327999200817104912 crossref_primary_10_1002_jbt_23406 crossref_primary_10_1080_01635581_2021_1957487 crossref_primary_10_1016_j_ajpath_2021_05_018 crossref_primary_10_4103_0304_4920_359799 crossref_primary_10_1186_s12951_025_03306_0 crossref_primary_10_3390_cancers12040927 crossref_primary_10_1186_s12885_024_12704_w crossref_primary_10_3389_fpubh_2021_650392 crossref_primary_10_1016_j_drudis_2023_103864 crossref_primary_10_1111_1759_7714_13328 crossref_primary_10_1016_j_jbc_2023_102961 crossref_primary_10_3390_genes13050885 crossref_primary_10_1111_1759_7714_14652 crossref_primary_10_1111_1759_7714_13321 crossref_primary_10_1177_17588359241284904 crossref_primary_10_3390_challe8020029 crossref_primary_10_1016_j_tranon_2020_100887 crossref_primary_10_3390_jcm9041000 crossref_primary_10_1002_jgm_3384 crossref_primary_10_1002_jcb_29559 crossref_primary_10_1016_j_prmcm_2023_100251 crossref_primary_10_1186_s12943_020_01256_9 crossref_primary_10_3390_ijms25094690 crossref_primary_10_1371_journal_pone_0182282 crossref_primary_10_1016_j_biocel_2020_105750 crossref_primary_10_1097_CJI_0000000000000397 crossref_primary_10_1002_cam4_4977 crossref_primary_10_1002_nbm_4204 crossref_primary_10_3389_fonc_2024_1358101 crossref_primary_10_3892_mmr_2021_12201 crossref_primary_10_1016_j_prp_2022_154031 crossref_primary_10_3390_biotech12030057 crossref_primary_10_1016_j_chest_2020_01_048 crossref_primary_10_2217_fon_2020_0583 crossref_primary_10_3390_molecules25081778 crossref_primary_10_3389_fgene_2023_1156230 crossref_primary_10_7888_juoeh_40_173 crossref_primary_10_1039_D0BM00970A crossref_primary_10_1177_1721727X221145447 crossref_primary_10_1038_s41698_023_00375_y crossref_primary_10_1001_jamanetworkopen_2019_6879 crossref_primary_10_1002_pon_5360 crossref_primary_10_1016_j_ijbiomac_2023_125453 crossref_primary_10_1615_CritRevEukaryotGeneExpr_2023047789 crossref_primary_10_1002_mc_23750 crossref_primary_10_3390_ijms222312836 crossref_primary_10_3390_ijms25126381 crossref_primary_10_1002_jbt_23037 crossref_primary_10_1016_j_biopha_2023_114486 crossref_primary_10_3389_fonc_2024_1402297 crossref_primary_10_18553_jmcp_2021_21308 crossref_primary_10_1016_j_cger_2017_06_008 crossref_primary_10_1038_s41419_024_06563_3 crossref_primary_10_3389_fendo_2023_1196372 crossref_primary_10_1186_s12885_022_09711_0 crossref_primary_10_1016_j_soc_2020_06_006 crossref_primary_10_1002_biof_2128 crossref_primary_10_3389_fimmu_2023_1133899 crossref_primary_10_1002_mgg3_1521 crossref_primary_10_3390_cancers13040830 crossref_primary_10_4155_fdd_2021_0006 crossref_primary_10_2147_CMAR_S244932 crossref_primary_10_3390_cancers11111619 crossref_primary_10_3389_fphar_2023_1090500 crossref_primary_10_1002_jcb_29542 crossref_primary_10_2147_IJGM_S367999 crossref_primary_10_1042_CS20190395 crossref_primary_10_1177_1758835918804151 crossref_primary_10_3233_CBM_190271 crossref_primary_10_1155_2022_3805013 crossref_primary_10_1002_mp_16839 crossref_primary_10_4102_sajo_v7i0_255 crossref_primary_10_3389_fimmu_2022_934494 crossref_primary_10_1016_j_compbiomed_2022_105394 crossref_primary_10_1002_jcp_28848 crossref_primary_10_1080_08820139_2025_2450246 crossref_primary_10_1097_MD_0000000000035086 crossref_primary_10_3390_cancers11121893 crossref_primary_10_1016_j_bmc_2024_117792 crossref_primary_10_14336_AD_2022_0407 crossref_primary_10_1002_prp2_528 crossref_primary_10_1038_s41392_019_0059_4 crossref_primary_10_3389_fimmu_2019_02215 crossref_primary_10_1186_s12967_019_1800_z crossref_primary_10_1080_21691401_2019_1647225 crossref_primary_10_2139_ssrn_4119538 crossref_primary_10_1371_journal_pone_0264645 crossref_primary_10_1016_j_gene_2024_148375 crossref_primary_10_4014_jmb_2102_02010 crossref_primary_10_3390_cancers11030415 crossref_primary_10_1155_2021_5917506 crossref_primary_10_1111_1759_7714_15013 crossref_primary_10_1021_acs_molpharmaceut_0c00052 crossref_primary_10_1186_s13045_022_01270_y crossref_primary_10_1016_j_ebiom_2022_104268 crossref_primary_10_1093_oncolo_oyac035 crossref_primary_10_1038_s41598_023_30073_5 crossref_primary_10_3390_biom10111521 crossref_primary_10_1515_oncologie_2023_0090 crossref_primary_10_1016_j_ebiom_2018_02_017 crossref_primary_10_1371_journal_pone_0254854 crossref_primary_10_1111_jcmm_17464 crossref_primary_10_3390_diagnostics11081432 crossref_primary_10_1080_14737167_2022_2078310 crossref_primary_10_1016_j_heliyon_2024_e35901 crossref_primary_10_1038_s41598_024_77500_9 crossref_primary_10_3389_fsurg_2022_890993 crossref_primary_10_1016_j_bcab_2020_101698 crossref_primary_10_1177_15347354241273962 crossref_primary_10_1021_acs_jafc_4c00882 crossref_primary_10_2147_IJGM_S330681 crossref_primary_10_2147_IJN_S346341 crossref_primary_10_1016_j_ctrv_2021_102225 crossref_primary_10_1177_1010428317695948 crossref_primary_10_1002_cam4_3614 crossref_primary_10_1039_D1NR08133K crossref_primary_10_1016_j_bmcl_2020_127394 crossref_primary_10_1371_journal_pone_0251357 crossref_primary_10_1080_07391102_2019_1587511 crossref_primary_10_1097_MD_0000000000018968 crossref_primary_10_1177_00469580221096259 crossref_primary_10_1111_jcmm_16582 crossref_primary_10_1016_j_ejmech_2019_111584 crossref_primary_10_18632_aging_202292 crossref_primary_10_1186_s13019_022_01788_9 crossref_primary_10_2147_OTT_S262084 crossref_primary_10_3390_antiox8120603 crossref_primary_10_1007_s13402_018_0404_6 crossref_primary_10_18632_aging_203140 crossref_primary_10_1155_2023_3377316 crossref_primary_10_1016_j_biocel_2020_105716 crossref_primary_10_3390_jcm11216590 crossref_primary_10_1111_1759_7714_14140 crossref_primary_10_1186_s12916_023_02849_z crossref_primary_10_1016_j_lungcan_2022_12_002 crossref_primary_10_3233_CBM_190222 crossref_primary_10_3233_CBM_220282 crossref_primary_10_1007_s00418_021_01966_1 crossref_primary_10_1097_COC_0000000000001116 crossref_primary_10_1097_CEJ_0000000000000566 crossref_primary_10_1371_journal_pone_0230444 crossref_primary_10_3390_ijms22115820 crossref_primary_10_1016_j_ejmech_2024_117130 crossref_primary_10_1097_MD_0000000000015450 crossref_primary_10_1038_s41388_021_01837_y crossref_primary_10_1007_s11748_023_01998_5 crossref_primary_10_3389_fcimb_2022_952297 crossref_primary_10_1080_14712598_2018_1508445 crossref_primary_10_1016_j_jtho_2019_08_011 crossref_primary_10_3389_fonc_2022_810526 crossref_primary_10_3390_cells12192393 crossref_primary_10_3748_wjg_v25_i32_4749 crossref_primary_10_1172_JCI160152 crossref_primary_10_1016_j_lungcan_2022_01_005 crossref_primary_10_1186_s13046_019_1079_1 crossref_primary_10_3390_genes15121497 crossref_primary_10_1016_j_cllc_2018_06_004 crossref_primary_10_1177_1533033820977546 crossref_primary_10_1038_s41420_021_00557_2 crossref_primary_10_1590_1414_431x20209317 crossref_primary_10_1186_s12890_022_02173_x crossref_primary_10_1016_j_biopha_2020_110461 crossref_primary_10_1016_j_indcrop_2023_116967 crossref_primary_10_1186_s12931_025_03127_7 crossref_primary_10_1177_1533033820977545 crossref_primary_10_1016_j_isci_2020_101411 crossref_primary_10_2174_1574888X18666230821104844 crossref_primary_10_1016_j_compbiomed_2023_106597 crossref_primary_10_1016_j_heliyon_2024_e39859 crossref_primary_10_1038_s41565_021_00872_w crossref_primary_10_1038_s41598_023_36720_1 crossref_primary_10_1002_cjp2_64 crossref_primary_10_1016_j_actbio_2023_05_030 crossref_primary_10_3892_ijmm_2018_3683 crossref_primary_10_2217_bmm_2019_0159 crossref_primary_10_7555_JBR_38_20240421 crossref_primary_10_1016_j_jmoldx_2019_01_001 crossref_primary_10_1136_jitc_2024_009165 crossref_primary_10_1016_j_heliyon_2022_e10866 crossref_primary_10_1007_s00432_024_05687_5 crossref_primary_10_1177_1934578X221127960 crossref_primary_10_1007_s11010_017_3170_2 crossref_primary_10_1016_j_lfs_2020_118942 crossref_primary_10_1038_s41598_023_35122_7 crossref_primary_10_1039_D4AY01685H crossref_primary_10_1002_ptr_6878 crossref_primary_10_1016_j_phrs_2020_105231 crossref_primary_10_3389_fneur_2022_878947 crossref_primary_10_1016_j_jbo_2019_100251 crossref_primary_10_1200_PO_21_00325 crossref_primary_10_3389_pore_2023_1611086 crossref_primary_10_3390_ma12182889 crossref_primary_10_1038_s41420_022_01040_2 crossref_primary_10_3389_fonc_2023_1124520 crossref_primary_10_1186_s13046_024_02989_x crossref_primary_10_1016_j_heliyon_2024_e24378 crossref_primary_10_1016_j_lungcan_2024_107533 crossref_primary_10_1002_ptr_6860 crossref_primary_10_2139_ssrn_4166783 crossref_primary_10_3389_fphar_2024_1516650 crossref_primary_10_3390_cancers12051107 crossref_primary_10_3389_fphar_2019_01178 crossref_primary_10_52547_JoMMID_11_1_1 crossref_primary_10_1016_j_lfs_2023_121749 crossref_primary_10_1016_j_ejphar_2020_173647 crossref_primary_10_1016_j_ejphar_2019_04_016 crossref_primary_10_1089_jpm_2020_0504 crossref_primary_10_1007_s00520_020_05856_5 crossref_primary_10_1016_j_ejphar_2023_175883 crossref_primary_10_1155_2022_3918926 crossref_primary_10_7759_cureus_8607 crossref_primary_10_1002_jcla_23357 crossref_primary_10_1016_j_biopha_2019_109493 crossref_primary_10_1016_j_lungcan_2021_06_022 crossref_primary_10_3390_cancers14051350 crossref_primary_10_3389_fgene_2022_997319 crossref_primary_10_1177_03936155221088882 crossref_primary_10_3892_etm_2021_10390 crossref_primary_10_1111_jcmm_17057 crossref_primary_10_1002_jcla_24691 crossref_primary_10_1016_j_heliyon_2024_e24397 crossref_primary_10_1007_s11548_022_02694_0 crossref_primary_10_3389_fonc_2020_01098 crossref_primary_10_1016_j_cca_2021_03_010 crossref_primary_10_1002_mc_23378 crossref_primary_10_1186_s40164_024_00520_8 crossref_primary_10_1016_j_jddst_2022_103268 crossref_primary_10_1016_j_jacc_2019_03_500 crossref_primary_10_1016_j_bioactmat_2023_04_005 crossref_primary_10_1002_adfm_202208220 crossref_primary_10_3389_fonc_2022_1092355 crossref_primary_10_1093_carcin_bgac090 crossref_primary_10_1186_s12967_020_02485_8 crossref_primary_10_1016_j_radmp_2023_01_003 crossref_primary_10_5761_atcs_oa_21_00237 crossref_primary_10_1111_jcmm_18387 crossref_primary_10_1016_j_ajps_2022_100773 crossref_primary_10_2217_pme_2019_0108 crossref_primary_10_1007_s12094_024_03556_8 crossref_primary_10_1016_j_lfs_2020_118985 crossref_primary_10_1111_ijcp_14317 crossref_primary_10_1007_s12038_022_00299_y crossref_primary_10_3390_molecules22091525 crossref_primary_10_1093_annonc_mdz002 crossref_primary_10_1097_CAD_0000000000001349 crossref_primary_10_3390_ijms23031565 crossref_primary_10_3389_fonc_2022_800315 crossref_primary_10_1016_j_addr_2021_113953 crossref_primary_10_1016_j_clae_2024_102134 crossref_primary_10_3389_fimmu_2022_1026214 crossref_primary_10_1016_j_bbadis_2023_166789 crossref_primary_10_1016_j_vhri_2018_05_001 crossref_primary_10_1038_s41419_021_03392_6 crossref_primary_10_1002_acm2_12545 crossref_primary_10_1155_2021_9568057 crossref_primary_10_3389_fonc_2022_949111 crossref_primary_10_2217_imt_2022_0178 crossref_primary_10_1007_s11302_021_09785_8 crossref_primary_10_1007_s00262_021_02847_1 crossref_primary_10_1093_abt_tbac006 crossref_primary_10_3389_fonc_2021_657283 crossref_primary_10_3390_cancers13061397 crossref_primary_10_1007_s12672_024_01257_w crossref_primary_10_1631_jzus_B2100170 crossref_primary_10_1186_s12885_021_07846_0 crossref_primary_10_1016_j_microc_2021_107035 crossref_primary_10_3389_fbioe_2020_00003 crossref_primary_10_3389_fonc_2022_916681 crossref_primary_10_1007_s10585_023_10219_5 crossref_primary_10_2174_1389201023666220818085945 crossref_primary_10_1080_14712598_2022_2072206 crossref_primary_10_1038_s41598_024_75650_4 crossref_primary_10_3389_fgene_2022_979928 crossref_primary_10_1155_2021_5005459 crossref_primary_10_1016_j_canlet_2022_215716 crossref_primary_10_1038_s41598_024_83276_9 crossref_primary_10_1038_s41417_022_00560_4 crossref_primary_10_1186_s12916_022_02580_1 crossref_primary_10_1080_14737140_2024_2305352 crossref_primary_10_1007_s00018_022_04360_9 crossref_primary_10_1111_cas_14125 crossref_primary_10_3389_fgene_2023_1120815 crossref_primary_10_1038_s41419_023_06125_z crossref_primary_10_1016_j_cell_2020_05_043 crossref_primary_10_1186_s12916_022_02362_9 crossref_primary_10_4103_lungindia_lungindia_305_17 crossref_primary_10_3390_ijms23010436 crossref_primary_10_3390_cancers15072190 crossref_primary_10_1080_15384047_2024_2392902 crossref_primary_10_3390_ijms25031897 crossref_primary_10_1016_j_intimp_2024_111781 crossref_primary_10_3390_ijms25031411 crossref_primary_10_3389_fphar_2020_568032 crossref_primary_10_1007_s42399_019_00066_5 crossref_primary_10_3390_molecules28020750 crossref_primary_10_1016_j_critrevonc_2024_104284 crossref_primary_10_1016_j_intimp_2022_108816 crossref_primary_10_1016_j_cllc_2020_09_004 crossref_primary_10_1155_2020_8571932 crossref_primary_10_1016_j_cllc_2020_09_005 crossref_primary_10_1111_1759_7714_14758 crossref_primary_10_1016_j_ejmech_2023_115477 crossref_primary_10_3389_fcvm_2022_879351 crossref_primary_10_18632_aging_202685 crossref_primary_10_1007_s00761_019_0552_y crossref_primary_10_1007_s11912_021_01105_y crossref_primary_10_1186_s12935_020_01402_9 crossref_primary_10_1007_s10103_024_04176_y crossref_primary_10_1152_ajplung_00364_2018 crossref_primary_10_18632_aging_204838 crossref_primary_10_3390_ijms26031066 crossref_primary_10_1155_2021_6905985 crossref_primary_10_1097_ACO_0000000000000669 crossref_primary_10_3390_cancers14071657 crossref_primary_10_1016_j_molstruc_2024_139067 crossref_primary_10_1097_JOM_0000000000002115 crossref_primary_10_3389_fonc_2022_962173 crossref_primary_10_1097_CAD_0000000000000640 crossref_primary_10_1186_s13062_023_00385_7 crossref_primary_10_1097_COC_0000000000000508 crossref_primary_10_1039_D4RA07467J crossref_primary_10_2174_0113816128263069231010111347 crossref_primary_10_1007_s00044_018_2224_7 crossref_primary_10_3389_fphar_2024_1382787 crossref_primary_10_1186_s11671_019_3139_z crossref_primary_10_1007_s12033_024_01127_4 crossref_primary_10_1111_his_14855 crossref_primary_10_3390_ijms241914614 crossref_primary_10_1002_mco2_70128 crossref_primary_10_3233_CBM_203197 crossref_primary_10_1038_s41598_024_76196_1 crossref_primary_10_1126_scitranslmed_aat5690 crossref_primary_10_3390_cancers17040621 crossref_primary_10_1111_cpr_12461 crossref_primary_10_1007_s10741_019_09876_0 crossref_primary_10_18632_aging_202663 crossref_primary_10_3389_fonc_2020_00855 crossref_primary_10_1007_s00262_021_03091_3 crossref_primary_10_1186_s12575_024_00245_2 crossref_primary_10_3390_ijms22168405 crossref_primary_10_1016_j_gendis_2021_05_005 crossref_primary_10_1001_jamaoncol_2020_6332 crossref_primary_10_1136_jitc_2021_002746 crossref_primary_10_1177_1533033820977504 crossref_primary_10_1371_journal_pone_0239614 crossref_primary_10_3390_ijms18060860 crossref_primary_10_1002_cam4_6543 crossref_primary_10_1186_s12935_020_01183_1 crossref_primary_10_1186_s40364_022_00412_1 crossref_primary_10_1111_1759_7714_13856 crossref_primary_10_1159_000537819 crossref_primary_10_1371_journal_pone_0227634 crossref_primary_10_1007_s11033_024_09477_7 crossref_primary_10_1096_fj_202200005RR crossref_primary_10_3390_ijms23042053 crossref_primary_10_1136_jitc_2023_007766 crossref_primary_10_1016_j_prp_2020_153144 crossref_primary_10_1038_s41467_021_25032_5 crossref_primary_10_1038_s41598_024_78159_y crossref_primary_10_1111_jcmm_14609 crossref_primary_10_1093_ejcts_ezaa215 crossref_primary_10_1007_s00210_023_02859_x crossref_primary_10_1155_2022_4153211 crossref_primary_10_1007_s12210_021_00996_0 crossref_primary_10_1007_s00432_023_05437_z crossref_primary_10_3389_fphys_2022_946099 crossref_primary_10_3390_cancers13081812 crossref_primary_10_1016_j_intimp_2022_108806 crossref_primary_10_7189_jogh_14_04067 crossref_primary_10_1038_s41598_022_10598_x crossref_primary_10_1111_1759_7714_13836 crossref_primary_10_1158_1055_9965_EPI_24_1096 crossref_primary_10_1016_j_biopsych_2023_07_007 crossref_primary_10_3390_molecules26237344 crossref_primary_10_1634_theoncologist_2020_0545 crossref_primary_10_18632_oncotarget_16674 crossref_primary_10_1002_tox_24284 crossref_primary_10_1016_j_bulcan_2019_11_011 crossref_primary_10_1097_MD_0000000000008258 crossref_primary_10_1016_j_ncrna_2024_09_004 crossref_primary_10_3389_fonc_2022_802467 crossref_primary_10_1016_j_critrevonc_2022_103610 crossref_primary_10_1038_s41598_021_94671_x crossref_primary_10_1007_s12672_022_00600_3 crossref_primary_10_1371_journal_pone_0282888 crossref_primary_10_3390_molecules26164711 crossref_primary_10_1007_s00775_019_01644_7 crossref_primary_10_3389_fimmu_2023_1297577 crossref_primary_10_1186_s12957_022_02556_8 crossref_primary_10_1200_PO_22_00651 crossref_primary_10_3389_fimmu_2022_1008778 crossref_primary_10_1093_bioadv_vbac100 crossref_primary_10_1016_j_mcp_2020_101652 crossref_primary_10_3389_fimmu_2022_806877 crossref_primary_10_3389_fonc_2023_1022862 crossref_primary_10_1111_cas_14519 crossref_primary_10_3389_fimmu_2020_622467 crossref_primary_10_1097_MD_0000000000035005 crossref_primary_10_1111_jcmm_15997 crossref_primary_10_1007_s10637_018_0698_2 crossref_primary_10_3892_ol_2020_11631 crossref_primary_10_1007_s00432_024_05637_1 crossref_primary_10_1016_j_biopha_2021_111390 crossref_primary_10_3390_ph15070786 crossref_primary_10_1016_j_rceng_2022_05_006 crossref_primary_10_1186_s12885_024_13083_y crossref_primary_10_2147_CMAR_S352308 crossref_primary_10_1158_0008_5472_CAN_20_3941 crossref_primary_10_2147_OTT_S322852 crossref_primary_10_3389_fgene_2021_771062 crossref_primary_10_1186_s12885_022_09696_w crossref_primary_10_1002_advs_202403202 crossref_primary_10_1097_MD_0000000000023012 crossref_primary_10_1002_ddr_21873 crossref_primary_10_3892_ol_2022_13558 crossref_primary_10_1002_1878_0261_12847 crossref_primary_10_1016_j_rmcr_2020_101064 crossref_primary_10_18632_aging_205314 crossref_primary_10_1186_s12943_022_01525_9 crossref_primary_10_31083_j_fbl2804075 crossref_primary_10_1177_1479973121994783 crossref_primary_10_1016_j_genhosppsych_2019_04_001 crossref_primary_10_3389_fimmu_2021_774807 crossref_primary_10_1186_s13046_020_01555_5 crossref_primary_10_1111_jcmm_14649 crossref_primary_10_1002_ptr_8241 crossref_primary_10_2174_1568009622666220831142452 crossref_primary_10_4236_jct_2024_158028 crossref_primary_10_1080_21655979_2021_1954840 crossref_primary_10_1016_j_omto_2022_01_012 crossref_primary_10_1097_MD_0000000000033297 crossref_primary_10_1007_s00432_018_02826_7 crossref_primary_10_3389_fonc_2022_898920 crossref_primary_10_1016_j_phymed_2021_153742 crossref_primary_10_1016_j_heliyon_2023_e22200 crossref_primary_10_1016_j_heliyon_2023_e22201 crossref_primary_10_1016_j_bios_2019_01_062 crossref_primary_10_1007_s10142_024_01330_1 crossref_primary_10_1186_s12885_021_08539_4 crossref_primary_10_2147_OTT_S281517 crossref_primary_10_1016_j_bcp_2024_116155 crossref_primary_10_2147_RMI_S176901 crossref_primary_10_1097_MD_0000000000035483 crossref_primary_10_2217_imt_2021_0035 crossref_primary_10_3892_ol_2023_13974 crossref_primary_10_1080_13880209_2019_1672756 crossref_primary_10_1097_MD_0000000000024793 crossref_primary_10_1080_21655979_2022_2031672 crossref_primary_10_1016_j_isci_2024_109869 crossref_primary_10_1186_s13287_021_02160_9 crossref_primary_10_1016_j_prp_2021_153497 crossref_primary_10_1186_s13045_021_01123_0 crossref_primary_10_1016_j_mcp_2022_101849 crossref_primary_10_1038_s41598_023_31400_6 crossref_primary_10_1016_j_molstruc_2022_132691 crossref_primary_10_1089_dna_2021_0900 crossref_primary_10_1080_15384101_2019_1678966 crossref_primary_10_1007_s00520_022_06987_7 crossref_primary_10_1002_onco_13548 crossref_primary_10_1042_BSR20201541 crossref_primary_10_1186_s12935_019_1041_5 crossref_primary_10_1177_11795549221116834 crossref_primary_10_3389_fimmu_2022_872387 crossref_primary_10_3889_oamjms_2022_9275 crossref_primary_10_1038_s41420_022_01004_6 crossref_primary_10_3389_fonc_2021_714357 crossref_primary_10_1016_j_phrs_2019_104415 crossref_primary_10_1016_j_modpat_2023_100209 crossref_primary_10_1097_MD_0000000000027841 crossref_primary_10_3233_CBM_191268 crossref_primary_10_1016_j_lfs_2022_120602 crossref_primary_10_1016_j_ctrv_2018_04_006 crossref_primary_10_1111_hex_13457 crossref_primary_10_3389_fonc_2021_656509 crossref_primary_10_1186_s12885_021_08570_5 crossref_primary_10_1016_j_cellsig_2024_111221 crossref_primary_10_1186_s12885_021_08472_6 crossref_primary_10_1002_ptr_8202 crossref_primary_10_3892_ol_2019_10436 crossref_primary_10_3389_fonc_2020_00424 crossref_primary_10_18632_aging_203540 crossref_primary_10_2174_0118715206289038240214102951 crossref_primary_10_1016_j_rmcr_2019_02_015 crossref_primary_10_1021_acs_chemrev_3c00776 crossref_primary_10_55905_cuadv16n12_047 crossref_primary_10_1007_s12325_019_00903_y crossref_primary_10_1038_s41598_021_85797_z crossref_primary_10_1136_bmjopen_2022_061367 crossref_primary_10_1186_s12967_018_1516_5 crossref_primary_10_1002_cam4_4310 crossref_primary_10_1016_j_bcp_2020_114062 crossref_primary_10_1016_j_omtn_2019_04_004 crossref_primary_10_1039_D4MD00367E crossref_primary_10_1186_s13046_021_02230_z crossref_primary_10_1080_1040841X_2023_2247493 crossref_primary_10_1016_j_biopha_2022_113835 crossref_primary_10_1016_j_clim_2020_108620 crossref_primary_10_3389_fonc_2021_705869 crossref_primary_10_1016_j_rmcr_2019_100954 crossref_primary_10_1136_spcare_2023_004558 crossref_primary_10_2147_PGPM_S325788 crossref_primary_10_1007_s12094_021_02713_7 crossref_primary_10_1042_BSR20202444 crossref_primary_10_3389_fonc_2024_1428307 crossref_primary_10_1186_s12885_022_10232_z crossref_primary_10_3390_ijms241310545 crossref_primary_10_1111_1759_7714_15162 crossref_primary_10_1007_s10585_025_10336_3 crossref_primary_10_7717_peerj_10225 crossref_primary_10_3389_fonc_2021_652567 crossref_primary_10_1080_19336918_2020_1766308 crossref_primary_10_1007_s13353_020_00569_1 crossref_primary_10_1089_dna_2021_0024 crossref_primary_10_1186_s12943_021_01307_9 crossref_primary_10_1186_s12957_023_03064_z crossref_primary_10_1039_D0NR00080A crossref_primary_10_1111_febs_16933 crossref_primary_10_3233_THC_220165 crossref_primary_10_1002_mco2_105 crossref_primary_10_1002_mco2_102 crossref_primary_10_1080_1744666X_2022_2088510 crossref_primary_10_1186_s13046_020_01772_y crossref_primary_10_1016_j_asjsur_2024_05_257 crossref_primary_10_1016_j_surfin_2024_105436 crossref_primary_10_1097_MD_0000000000026488 crossref_primary_10_1016_j_trecan_2022_11_003 crossref_primary_10_1016_j_biopha_2022_112927 crossref_primary_10_1038_s41698_017_0032_z crossref_primary_10_1111_1759_7714_15170 crossref_primary_10_2147_IJGM_S348912 crossref_primary_10_1177_0141076819843654 crossref_primary_10_1002_jcla_24382 crossref_primary_10_1212_CON_0000000000000551 crossref_primary_10_4103_wjtcm_wjtcm_96_24 crossref_primary_10_3390_ijms22031019 crossref_primary_10_2147_CMAR_S272277 crossref_primary_10_2174_1871520622666220509175305 crossref_primary_10_1007_s00289_023_05072_1 crossref_primary_10_1001_jamaoncol_2019_2553 crossref_primary_10_1016_j_tice_2021_101495 crossref_primary_10_3389_fonc_2022_997702 crossref_primary_10_1002_jcla_24396 crossref_primary_10_3389_fphar_2022_1081244 crossref_primary_10_1002_mco2_564 crossref_primary_10_3390_cancers13061403 crossref_primary_10_3389_fcell_2020_00064 crossref_primary_10_1002_ange_202009983 crossref_primary_10_1016_j_omton_2024_200788 crossref_primary_10_3727_096504017X15009792179602 crossref_primary_10_3389_fmed_2023_1080121 crossref_primary_10_1111_1759_7714_15152 crossref_primary_10_3892_ijo_2020_4993 crossref_primary_10_5937_afmnai39_35741 crossref_primary_10_1016_j_biopha_2021_111317 crossref_primary_10_18632_oncotarget_22860 crossref_primary_10_3390_genes14081551 crossref_primary_10_1136_jitc_2020_000733 crossref_primary_10_2147_VHRM_S463648 crossref_primary_10_1097_CAD_0000000000001045 crossref_primary_10_1038_s41598_021_90755_w crossref_primary_10_1007_s00210_019_01746_8 crossref_primary_10_1038_s41598_025_88964_8 crossref_primary_10_1155_2022_9139823 crossref_primary_10_1111_1759_7714_15121 crossref_primary_10_1016_j_heliyon_2020_e05639 crossref_primary_10_3233_CBM_210376 crossref_primary_10_1016_j_cmpb_2023_107864 crossref_primary_10_32604_or_2022_03563 crossref_primary_10_1590_1414_431x2021e11513 crossref_primary_10_1038_s41598_022_05997_z crossref_primary_10_1002_ccr3_7417 crossref_primary_10_1186_s12885_022_09366_x crossref_primary_10_1177_1078155220959428 crossref_primary_10_1002_JLB_1MA0422_208R crossref_primary_10_1155_2021_9922185 crossref_primary_10_1097_MD_0000000000036267 crossref_primary_10_1002_adtp_202100184 crossref_primary_10_1159_000541990 crossref_primary_10_1002_mc_23654 crossref_primary_10_3390_cancers14143323 crossref_primary_10_1016_j_canlet_2020_01_030 crossref_primary_10_1002_ijc_34467 crossref_primary_10_1080_21655979_2021_2011631 crossref_primary_10_1016_j_canlet_2024_216835 crossref_primary_10_1139_bcb_2019_0435 crossref_primary_10_1111_jcmm_16497 crossref_primary_10_1177_10781552251322452 crossref_primary_10_31083_j_fbl2908296 crossref_primary_10_3389_fonc_2023_847182 crossref_primary_10_1186_s13046_024_03077_w crossref_primary_10_2147_CMAR_S290966 crossref_primary_10_1038_s41598_022_11805_5 crossref_primary_10_1002_ijc_33132 crossref_primary_10_23736_S0026_4806_20_06444_7 crossref_primary_10_1042_BSR20201140 crossref_primary_10_2217_fon_2023_0469 crossref_primary_10_1016_j_biopha_2023_115491 crossref_primary_10_1016_j_jaccao_2020_02_005 crossref_primary_10_1002_adbi_202400119 crossref_primary_10_1016_j_bulcan_2020_12_007 crossref_primary_10_3839_jabc_2023_038 crossref_primary_10_1016_j_prp_2023_154440 crossref_primary_10_1016_j_clim_2021_108872 crossref_primary_10_1016_j_ejphar_2021_174284 crossref_primary_10_1080_01480545_2018_1523921 crossref_primary_10_1016_j_micpath_2023_106197 crossref_primary_10_1007_s00280_019_03843_0 crossref_primary_10_1155_2022_3198590 crossref_primary_10_1080_0284186X_2019_1637539 crossref_primary_10_3892_ol_2019_10964 crossref_primary_10_1016_j_isci_2023_108648 crossref_primary_10_1155_2020_8359860 crossref_primary_10_15324_kjcls_2023_55_2_93 crossref_primary_10_1016_j_gpb_2022_10_006 crossref_primary_10_3390_cancers14041030 crossref_primary_10_1016_j_biocel_2022_106293 crossref_primary_10_3892_etm_2022_11172 crossref_primary_10_1186_s12885_024_12175_z crossref_primary_10_1016_j_gene_2022_146962 crossref_primary_10_2147_CMAR_S258370 crossref_primary_10_1186_s10020_024_00879_8 crossref_primary_10_3390_cancers11111782 crossref_primary_10_1111_1759_7714_13818 crossref_primary_10_1080_21655979_2022_2053810 crossref_primary_10_3390_ijms24065626 crossref_primary_10_34197_ats_scholar_2021_0032RE crossref_primary_10_1080_07853890_2024_2447930 crossref_primary_10_3389_fimmu_2024_1500996 crossref_primary_10_1016_j_bbcan_2021_188577 crossref_primary_10_1186_s12935_019_0800_7 crossref_primary_10_3389_fonc_2020_568059 crossref_primary_10_1186_s12935_024_03402_5 crossref_primary_10_1016_j_ejmech_2019_111648 crossref_primary_10_1016_j_phymed_2023_154732 crossref_primary_10_1016_j_tranon_2021_101163 crossref_primary_10_1136_jcp_2024_209514 crossref_primary_10_1016_j_bcp_2021_114808 crossref_primary_10_1007_s12672_025_02096_z crossref_primary_10_1016_j_prp_2020_153101 crossref_primary_10_1016_j_celrep_2020_01_037 crossref_primary_10_1016_j_wneu_2020_05_273 crossref_primary_10_1038_s41419_020_03198_y crossref_primary_10_1016_j_canlet_2022_215783 crossref_primary_10_3390_diagnostics14100998 crossref_primary_10_1007_s10334_021_00916_1 crossref_primary_10_1158_1541_7786_MCR_22_0984 crossref_primary_10_1002_tox_22922 crossref_primary_10_1002_jcla_23450 crossref_primary_10_1007_s13258_021_01190_0 crossref_primary_10_3892_ijmm_2019_4396 crossref_primary_10_1016_j_phrs_2020_105110 crossref_primary_10_1016_j_jchromb_2021_122940 crossref_primary_10_3389_fimmu_2021_742080 crossref_primary_10_1186_s12951_021_00804_9 crossref_primary_10_1186_s12935_022_02699_4 crossref_primary_10_3389_fonc_2022_1005668 crossref_primary_10_1016_j_yexcr_2023_113583 crossref_primary_10_3390_ijms18010222 crossref_primary_10_3390_ijms232214054 crossref_primary_10_3389_fonc_2020_559568 crossref_primary_10_4251_wjgo_v13_i5_366 crossref_primary_10_1016_j_cej_2022_135240 crossref_primary_10_1016_j_cej_2024_157232 crossref_primary_10_1038_s41598_018_34160_w crossref_primary_10_1038_s41420_024_02101_4 crossref_primary_10_3389_fimmu_2022_1007812 crossref_primary_10_1080_14740338_2020_1764936 crossref_primary_10_3233_CBM_201045 crossref_primary_10_1172_JCI172278 crossref_primary_10_1155_2020_5981870 crossref_primary_10_1183_23120541_00105_2022 crossref_primary_10_1038_s41419_017_0063_y crossref_primary_10_1186_s12935_023_03068_5 crossref_primary_10_2214_AJR_18_19856 crossref_primary_10_1038_s41419_024_07081_y crossref_primary_10_1038_s41420_024_02256_0 crossref_primary_10_1166_jbn_2023_3609 crossref_primary_10_3389_fcell_2022_979262 crossref_primary_10_1016_j_biopha_2021_111716 crossref_primary_10_1093_biomethods_bpac012 crossref_primary_10_3724_abbs_2022005 crossref_primary_10_1002_cnr2_1483 crossref_primary_10_1016_j_intimp_2023_110251 crossref_primary_10_1038_s41598_023_47328_w crossref_primary_10_1186_s12885_023_11812_3 crossref_primary_10_1007_s00432_020_03379_4 crossref_primary_10_1016_j_yexcr_2021_112914 crossref_primary_10_1111_cas_16274 crossref_primary_10_1177_18758592241306682 crossref_primary_10_1016_j_cllc_2018_11_014 crossref_primary_10_1186_s13046_018_0894_0 crossref_primary_10_1111_cas_16273 crossref_primary_10_1038_s41590_023_01428_x crossref_primary_10_1016_j_jss_2024_06_005 crossref_primary_10_7759_cureus_55885 crossref_primary_10_1002_jssc_201801165 crossref_primary_10_1007_s00775_022_01933_8 crossref_primary_10_1186_s10020_024_00813_y crossref_primary_10_1155_2021_6686158 crossref_primary_10_1080_15384101_2021_1995130 crossref_primary_10_1097_CAD_0000000000001477 crossref_primary_10_3892_ol_2024_14353 crossref_primary_10_1002_crt2_8 crossref_primary_10_1002_1878_0261_13323 crossref_primary_10_1016_j_ejca_2022_05_011 crossref_primary_10_3389_fimmu_2022_1110774 crossref_primary_10_2147_OTT_S261054 crossref_primary_10_1002_pon_5030 crossref_primary_10_3389_fphar_2024_1491400 crossref_primary_10_1038_s41571_018_0115_y crossref_primary_10_1186_s13045_020_00915_0 crossref_primary_10_1007_s10876_019_01650_4 crossref_primary_10_1186_s12943_020_1133_9 crossref_primary_10_1038_s41467_022_29647_0 crossref_primary_10_1016_j_jtocrr_2023_100530 crossref_primary_10_18632_aging_103319 crossref_primary_10_1038_s41419_022_05316_4 crossref_primary_10_2147_OTT_S254735 crossref_primary_10_1016_j_acra_2020_06_010 crossref_primary_10_1080_01635581_2020_1823439 crossref_primary_10_1186_s12931_020_01608_5 crossref_primary_10_1016_j_carbon_2024_119065 crossref_primary_10_20996_1819_6446_2020_02_05 crossref_primary_10_1002_pon_5033 crossref_primary_10_3390_molecules27165292 crossref_primary_10_1186_s12885_021_08655_1 crossref_primary_10_1016_j_wneu_2020_08_098 crossref_primary_10_3389_fonc_2022_927440 crossref_primary_10_1016_j_semcancer_2023_01_006 crossref_primary_10_1186_s12931_021_01780_2 crossref_primary_10_1111_cpr_13402 crossref_primary_10_1021_acsomega_2c07647 crossref_primary_10_1002_mco2_70036 crossref_primary_10_1016_j_biopsych_2018_02_013 crossref_primary_10_1016_j_cca_2018_08_034 crossref_primary_10_1177_1724600818772194 crossref_primary_10_3390_cancers15102858 crossref_primary_10_1186_s40001_023_01585_7 crossref_primary_10_1007_s12013_024_01352_3 crossref_primary_10_1016_j_heliyon_2024_e37100 crossref_primary_10_2174_0118715206262252231004110310 crossref_primary_10_2147_JIR_S399193 crossref_primary_10_3390_ijms241310576 crossref_primary_10_3727_096504021X16328213967104 crossref_primary_10_1155_2020_9548632 crossref_primary_10_1515_cclm_2022_1033 crossref_primary_10_1016_j_carbpol_2025_123368 crossref_primary_10_1016_j_ctarc_2022_100603 crossref_primary_10_3892_or_2021_8166 crossref_primary_10_1021_acs_molpharmaceut_8b00161 crossref_primary_10_3389_fphar_2020_00945 crossref_primary_10_1186_s12943_022_01662_1 crossref_primary_10_3389_fonc_2024_1471109 crossref_primary_10_1016_j_scib_2020_12_027 crossref_primary_10_1248_bpb_b21_00843 crossref_primary_10_3389_fonc_2021_603595 crossref_primary_10_1016_j_lungcan_2022_08_006 crossref_primary_10_4103_2311_8571_385513 crossref_primary_10_1515_biol_2022_0977
Cites_doi	10.1200/JCO.2012.45.6095 10.1148/radiol.2015142554 10.1200/jco.2014.32.15_suppl.8000 10.1038/nature14011 10.1378/chest.10-2745 10.1200/jco.2010.28.15_suppl.7506 10.1016/S1470-2045(16)00099-1 10.1016/S1470-2045(12)70344-3 10.1200/JCO.2010.33.1280 10.1016/j.jtho.2015.09.016 10.1200/JCO.2012.44.2806 10.1016/S1470-2045(15)00121-7 10.5858/arpa.2015-0522-SA 10.1371/journal.pone.0071379 10.1016/S1470-2045(09)70364-X 10.1158/1078-0432.CCR-13-0318 10.1016/S0959-8049(15)30068-X 10.1093/annonc/mdv186 10.1093/annonc/mdu089 10.1016/S1470-2045(14)71207-0 10.1016/S1470-2045(14)70389-4 10.1001/jama.2010.261 10.1016/j.lungcan.2012.09.016 10.1055/s-0033-1358615 10.1038/nm.3854 10.1016/j.jtcvs.2013.11.001 10.1093/annonc/mdu349.71 10.1097/JTO.0b013e3182745948 10.1200/JOP.2015.009068 10.1016/S1470-2045(12)70489-8 10.1158/1078-0432.CCR-13-2482 10.1200/jco.2015.33.15_suppl.8060 10.1056/NEJMoa1214886 10.1158/1078-0432.CCR-14-2789 10.1200/JCO.2009.22.6993 10.1056/NEJMoa1006448 10.1200/JCO.2012.47.1102 10.7326/M14-2086 10.1200/JCO.2008.17.1405 10.1016/S1470-2045(14)70381-X 10.1016/S1470-2045(16)30033-X 10.1200/jco.2015.33.15_suppl.8084 10.3322/caac.20102 10.1200/JCO.2014.58.3708 10.1038/nrc3239 10.1200/JCO.2011.35.9638 10.1056/NEJMoa1502309 10.1038/nrclinonc.2015.202 10.1158/1078-0432.CCR-14-2594 10.1200/JCO.2007.13.9030 10.1056/NEJMoa1411817 10.1200/JCO.2013.51.1816 10.1111/1759-7714.12287 10.1200/JCO.2014.59.0539 10.1016/S0140-6736(15)01281-7 10.1200/JCO.2014.59.4358 10.1056/NEJMc1506831 10.1093/ntr/ntv177 10.1016/j.cell.2007.11.025 10.1001/jamaoncol.2015.4921 10.1158/2159-8290.CD-13-0846 10.1056/NEJMoa1102873 10.1073/pnas.1420785112 10.1056/NEJMoa1406766 10.1200/jco.2015.33.15_suppl.8034 10.1200/JCO.2015.61.8918 10.1200/JCO.2011.35.6345 10.1200/JCO.2015.62.1342 10.1056/NEJMoa1504627 10.1016/j.jtho.2015.09.009 10.1056/NEJMoa1507643 10.1200/jco.2015.33.15_suppl.7503 10.1016/j.lungcan.2006.01.006 10.1158/1078-0432.CCR-14-2791 10.1016/S1470-2045(13)70254-7 10.1158/2159-8290.CD-15-0399 10.1016/S0959-8049(16)31938-4 10.1038/modpathol.2010.232 10.1016/S1470-2045(11)70393-X 10.1016/S0140-6736(13)62159-5 10.1016/j.ctrv.2015.03.009 10.1093/annonc/mdv270 10.1016/j.cllc.2014.10.003 10.1038/nature05945 10.1056/NEJMoa1215530 10.1200/jco.2015.33.15_suppl.8007 10.1097/JTO.0000000000000445 10.1016/S1470-2045(15)00483-0 10.1093/icvts/ivs472 10.1200/jco.2015.33.15_suppl.8059 10.1016/j.ijrobp.2008.11.042 10.1158/2159-8290.CD-13-0035 10.1016/S0140-6736(09)61497-5 10.1200/jco.2015.33.15_suppl.8006 10.1158/2159-8290.CD-14-1467 10.1200/JCO.2011.39.9766 10.1200/JCO.2011.39.9782 10.7326/0003-4819-158-4-201302190-00004 10.1016/j.jtho.2016.03.012 10.1126/scitranslmed.3002003 10.3322/caac.21239 10.1016/j.jtho.2016.01.012 10.1158/2159-8290.CD-15-0443 10.1126/scitranslmed.3001451 10.1093/jnci/dji096 10.1136/thoraxjnl-2015-207140 10.1200/JCO.2014.58.3302 10.1093/jnci/dji055 10.1056/NEJMoa1408440 10.1158/1078-0432.CCR-14-2958 10.1016/S1470-2045(10)70112-1 10.1002/ijc.29210 10.1021/acs.jmedchem.5b01073 10.1016/S1470-2045(15)00488-X 10.1200/JCO.2016.34.15_suppl.9008 10.1056/NEJMoa1501824 10.1016/S0140-6736(14)60845-X 10.1038/nature11404 10.1158/1078-0432.CCR-11-2906 10.1016/S0140-6736(16)00587-0 10.1056/NEJMoa1311107 10.1016/S1470-2045(13)70586-2 10.1200/JCO.2014.60.7317 10.1016/j.lungcan.2012.03.019 10.1093/jnci/djr325 10.1001/jamaoncol.2014.257 10.1200/JCO.2015.64.8824 10.1016/S1470-2045(16)00077-2 10.1200/JCO.2009.26.2543 10.1016/j.jtho.2016.05.008 10.1200/JCO.2012.43.9422 10.1016/S1470-2045(14)70362-6 10.1016/S1470-2045(15)00026-1 10.1016/j.jacr.2014.10.002 10.1093/annonc/mdt205 10.1158/2159-8274.CD-11-0005 10.1016/S1470-2045(13)70142-6 10.1503/cmaj.151421 10.1158/1078-0432.CCR-13-0731 10.1200/jco.2014.32.15_suppl.8001 10.1200/JCO.2012.44.1477 10.1200/jco.2015.33.15_suppl.8032
ContentType	Journal Article
Copyright	2017 Elsevier Ltd Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 21, 2017
Copyright_xml	– notice: 2017 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 21, 2017
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8
DOI	10.1016/S0140-6736(16)30958-8
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary Curriculum ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences ProQuest Consumer Health Database Health & Medical Collection (Alumni) Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-547X
EndPage	311
ExternalDocumentID	4307167481 27574741 10_1016_S0140_6736_16_30958_8 S0140673616309588 1_s2_0_S0140673616309588
Genre	Journal Article Review
GroupedDBID	--- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHHHB AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 AAYXX ADXHL AGQPQ AGRNS AIGII CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8
ID	FETCH-LOGICAL-c685t-133dd4a5cf36355844da60f3b865cf807ec3727972c27a240aae22a5d8826c083
IEDL.DBID	7X7
ISSN	0140-6736 1474-547X
IngestDate	Fri Jul 11 06:36:09 EDT 2025 Sat Aug 23 14:35:26 EDT 2025 Thu Apr 03 07:04:27 EDT 2025 Tue Jul 01 03:16:41 EDT 2025 Thu Apr 24 22:59:41 EDT 2025 Fri Feb 23 02:34:52 EST 2024 Tue Feb 25 20:09:26 EST 2025 Tue Aug 26 17:21:51 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10066
Language	English
License	Copyright © 2017 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c685t-133dd4a5cf36355844da60f3b865cf807ec3727972c27a240aae22a5d8826c083
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
OpenAccessLink	http://www.thelancet.com/article/S0140673616309588/pdf
PMID	27574741
PQID	1861147179
PQPubID	40246
PageCount	13
ParticipantIDs	proquest_miscellaneous_1859723161 proquest_journals_1861147179 pubmed_primary_27574741 crossref_citationtrail_10_1016_S0140_6736_16_30958_8 crossref_primary_10_1016_S0140_6736_16_30958_8 elsevier_sciencedirect_doi_10_1016_S0140_6736_16_30958_8 elsevier_clinicalkeyesjournals_1_s2_0_S0140673616309588 elsevier_clinicalkey_doi_10_1016_S0140_6736_16_30958_8
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2017-01-21
PublicationDateYYYYMMDD	2017-01-21
PublicationDate_xml	– month: 01 year: 2017 text: 2017-01-21 day: 21
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	The Lancet (British edition)
PublicationTitleAlternate	Lancet
PublicationYear	2017
Publisher	Elsevier Ltd Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited
References	Bergethon, Shaw, Ou (bib60) 2012; 30 Postow, Callahan, Woldchok (bib124) 2015; 33 Zhang, Zang, Xu (bib150) 2011; 140 Brodowicz, Krzakowski, Zwitter (bib147) 2006; 52 Yankelevitz, Yip, Smith (bib11) 2015; 277 (bib17) 2016; 188 Ferlay, Soerjomataram, Dikshit (bib1) 2015; 136 Gettinger, Bazhenova, Salgia (bib58) 2014; 25 Paik, Drilon, Fan (bib50) 2015; 5 Timmerman, Paulus, Galvin (bib29) 2010; 303 Shigematsu, Lin, Takahashi (bib71) 2005; 97 Seto, Kato, Nishio (bib89) 2014; 15 Perol, Chouaid, Perol (bib149) 2012; 30 Zhao, Fan, Ma (bib152) 2015; 10 bib28 Camidge, Bang, Kwak (bib95) 2012; 13 Rosell, Carcereny, Gervais (bib37) 2012; 13 Sadiq, Salgia (bib49) 2013; 31 Aberle, Adams, Berg (bib3) 2011; 365 Ercan, Choi, Yun (bib84) 2015; 21 (bib2) 2015 Pinsky, Gierada, Black (bib8) 2015; 162 Katayama, Lovly, Shaw (bib52) 2015; 21 Antonia, Bendel, Taylor (bib138) 2015; 33 Planchard, Kim, Mazieres (bib46) 2016; 17 Shaw, Kim, Nakagawa (bib54) 2013; 368 Nokihara, Hida, Kondo (bib104) 2016; 34 Hyman, Puzanov, Subbiah (bib45) 2015; 373 Borghaei, Paz-Ares, Horn (bib126) 2015; 373 Wu, Lee, Thongprasert (bib88) 2013; 14 Mazières, Gandara, Leighl (bib42) 2013; 8 Henschke, Yip, Yankelevitz (bib6) 2013; 158 Camidge, Ou, Shapiro (bib70) 2014; 32 Vansteenkiste, Cho, Vanakesa (bib121) 2016; 17 Scagliotti, von Pawel, Novello (bib107) 2015; 33 Park, Lee, Lee (bib78) 2015; 33 (bib135) June 16, 2016 Hirsch, Bunn (bib25) 2015; 12 Drilon, Wang, Hasanovic (bib67) 2013; 3 Goss, O'Callaghan, Lorimer (bib27) 2013; 31 Mazières, Zalcman, Crinò (bib63) 2015; 33 Sequist, Waltman, Dias-Santagata (bib76) 2011; 3 Herbst, Soria, Kowanetz (bib134) 2014; 515 Field, Duffy, Baldwin (bib5) 2015; 71 Kwak, Bang, Camidge (bib94) 2010; 363 Rizvi, Brahmer, Ou (bib129) 2015; 33 Kelly, Altorki, Eberhardt (bib24) 2015; 33 Park, Tan, O'Byrne (bib38) 2016; 17 Reck, Kaiser, Mellemgaard (bib118) 2014; 15 Oxnard, Paweletz, Kuang (bib86) 2014; 20 Belani, Waterhouse, Ghazal (bib148) 2010; 28 Yang, Chen, Yan (bib79) 2013; 79 Shaw, Yeap, Mino-Kenudson (bib51) 2009; 27 Quoix, Lena, Losonczy (bib122) 2016; 17 Wakelee HA, Dahlberg SE, Keller SM, et-al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): Results of E1505. World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 1608. Gainor, Varghese, Ou (bib53) 2013; 19 Villanti, Jiang, Abrams, Pyenson (bib14) 2013; 8 Shaw, Ou, Bang (bib61) 2014; 371 Frank, Christodoulou, Kazerooni (bib9) 2013; 34 (bib119) Dec 17, 2015 Paz-Ares, de Marinis, Dediu (bib144) 2013; 31 Ciuleanu, Brodowicz, Zielinski (bib142) 2009; 374 Weickhardt, Scheier, Burke (bib80) 2012; 7 Goldstraw, Chansky, Crowley (bib20) 2016; 11 Jänne, Yang, Kim (bib39) 2015; 372 Solomon, Mok, Kim (bib55) 2014; 371 Kim, Ahn, Shi (bib96) 2012; 30 Wu, Zhou, Liam (bib74) 2015; 26 Piotrowska, Niederst, Karlovich (bib77) 2015; 5 Dearden, Stevens, Wu, Blowers (bib110) 2013; 24 Drilon, Sima, Somwar (bib68) 2015; 33 Herbst, Baas, Kim (bib127) 2015; 387 Sequist, Yang, Yamamoto (bib73) 2013; 31 Kris, Camidge, Giaccone (bib48) 2015; 26 Auperin, Pechoux, Rolland (bib32) 2010; 28 Garon, Rizvi, Hui (bib132) 2015; 372 Marchetti, Felicioni, Malatesta (bib43) 2011; 29 Fidias, Dakhil, Lyss (bib146) 2009; 27 Gulley, Spigel, Chandler (bib130) 2015; 33 (bib23) 2014; 383 Friboulet, Li, Katayama (bib99) 2014; 4 Seto, Kiura, Nishio (bib103) 2013; 14 Horeweg, van Rosmalen, Heuvelmans (bib4) 2014; 15 Mok, Spigel, Felip (bib100) 2015; 33 Bailar (bib18) 1984; 130 Senan, Brade, Wang (bib34) 2016; 34 Vansteenkiste, Crinò, Dooms (bib19) 2014; 25 Behera, Owonikoko, Chen (bib151) 2012; 77 Bunn, Minna, Augustyn (bib114) 2016; 4 Mok, Wu, Lee (bib85) 2015; 21 Stahel, Dafni, Gautschi (bib90) 2015; 51 Bradley, Paulus, Komaki (bib33) 2015; 16 Mulshine, D'Amico (bib12) 2014; 64 Garon, Ciuleanu, Arrieta (bib117) 2014; 384 Fehrenbacher, Spira, Ballinger (bib128) 2016; 387 Michels, Scheel, Scheffler (bib106) 2016; 11 Doebele, Davis, Vaishnavi (bib69) 2015; 5 Karachaliou, Mayo-de las Casas, Queralt (bib87) 2015; 1 Kazerooni, Armstrong, Amorosa (bib7) 2015; 12 Flores, Bauer, Aye (bib13) 2014; 147 Sequist, Rolfe, Allen (bib40) 2015; 373 Thress, Paweletz, Felip (bib83) 2015; 21 Yang, Sequist, Geater (bib75) 2015; 16 Almquist, Mosalpuria, Ganti (bib116) 2016; 12 Masters, Temin, Azzoli (bib141) 2015; 33 Paik, Arcila, Fara (bib44) 2011; 29 Doebele, Pilling, Aisner (bib98) 2012; 18 Forde, Kelly, Brahmer (bib120) 2014; 20 Costa, Shaw, Ou (bib97) 2015; 33 Besse, Johnson, Janne (bib137) 2015; 51 Soria, Wu, Nakagawa (bib82) 2015; 16 (bib111) 2012; 489 Shaw, Kim, Mehra (bib56) 2014; 370 Zeng, Wang, Cheng (bib91) 2015; 58 Curran, Paulus, Langer (bib31) 2011; 103 Soria, Fløtten, Horn (bib133) 2015; 26 Awad, Katayama, McTigue (bib64) 2013; 368 Pardoll (bib123) 2012; 12 Rolfo, Passiglia, Castiglia (bib65) 2014; 3 Spigel, Edelman, O'Byrne (bib108) 2014; 32 Brahmer, Reckamp, Baas (bib125) 2015; 373 Pietanza, Byers, Minna (bib115) 2015; 21 Tan, Yom, Tsao (bib36) 2016; 11 Jänne, Shaw, Pereira (bib41) 2013; 14 Mitsudomi, Morita, Yatabe (bib72) 2010; 11 Zhou, Fan, Bu (bib16) 2015; 6 Boyle, Masago, Ellison, Yatabe, Hirsch (bib62) 2015; 16 Ramalingam, Owonikoko, Khuri (bib140) 2011; 61 Hammerman, Sos, Ramos (bib113) 2011; 1 Felip, Orlov, Park (bib102) 2015; 33 Gettinger, Horn, Gandhi (bib131) 2015; 33 Wang, Hu, Pan (bib105) 2012; 30 Tsao, Scagliotti, Bunn (bib35) 2016; 11 Kerr, Hirsch (bib136) 2016; 140 Shaw, Gandhi, Gadgeel (bib101) 2016; 17 Planchard, Groen, Kim (bib109) 2015; 33 Cappuzzo, Ciuleanu, Stelmakh (bib143) 2010; 11 Mazières, Peters, Lepage (bib47) 2013; 31 Yoshizawa, Motoi, Riely (bib10) 2011; 24 Zou, Li, Engstrom (bib59) 2015; 112 Pignon, Tribodet, Scagliotti (bib22) 2008; 26 Weiss, Sos, Seidel (bib112) 2010; 2 Fakiris, McGarry, Yiannoutsos (bib30) 2009; 75 Califano, Abidin, Tariq, Economopoulou, Metro, Mountzios (bib66) 2015; 41 Gadgeel, Gandhi, Riely (bib57) 2014; 15 Ostroff, Copeland, Borderud, Li, Shelley, Henschke (bib15) 2015; 18 Soda, Choi, Enomoto (bib92) 2007; 448 Rikova, Guo, Zeng (bib93) 2007; 131 Westeel, Quoix, Moro-Sibilot (bib145) 2005; 97 Cao, Manganas, Ang, Peeceeyen, Yan (bib21) 2013; 16 Park, Yu, Kim (bib81) 2016; 2 Alley EW, Schellens JH, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). IASLC 16th World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 3011. Shaw (10.1016/S0140-6736(16)30958-8_bib56) 2014; 370 Camidge (10.1016/S0140-6736(16)30958-8_bib95) 2012; 13 Pignon (10.1016/S0140-6736(16)30958-8_bib22) 2008; 26 Gulley (10.1016/S0140-6736(16)30958-8_bib130) 2015; 33 Vansteenkiste (10.1016/S0140-6736(16)30958-8_bib121) 2016; 17 (10.1016/S0140-6736(16)30958-8_bib111) 2012; 489 Vansteenkiste (10.1016/S0140-6736(16)30958-8_bib19) 2014; 25 Mok (10.1016/S0140-6736(16)30958-8_bib85) 2015; 21 Yoshizawa (10.1016/S0140-6736(16)30958-8_bib10) 2011; 24 Wu (10.1016/S0140-6736(16)30958-8_bib88) 2013; 14 Senan (10.1016/S0140-6736(16)30958-8_bib34) 2016; 34 (10.1016/S0140-6736(16)30958-8_bib135) 2016 Seto (10.1016/S0140-6736(16)30958-8_bib89) 2014; 15 Soria (10.1016/S0140-6736(16)30958-8_bib133) 2015; 26 Hyman (10.1016/S0140-6736(16)30958-8_bib45) 2015; 373 Park (10.1016/S0140-6736(16)30958-8_bib81) 2016; 2 Tsao (10.1016/S0140-6736(16)30958-8_bib35) 2016; 11 Doebele (10.1016/S0140-6736(16)30958-8_bib98) 2012; 18 Weickhardt (10.1016/S0140-6736(16)30958-8_bib80) 2012; 7 (10.1016/S0140-6736(16)30958-8_bib23) 2014; 383 Hammerman (10.1016/S0140-6736(16)30958-8_bib113) 2011; 1 Marchetti (10.1016/S0140-6736(16)30958-8_bib43) 2011; 29 Kelly (10.1016/S0140-6736(16)30958-8_bib24) 2015; 33 Bunn (10.1016/S0140-6736(16)30958-8_bib114) 2016; 4 Pietanza (10.1016/S0140-6736(16)30958-8_bib115) 2015; 21 Ercan (10.1016/S0140-6736(16)30958-8_bib84) 2015; 21 Planchard (10.1016/S0140-6736(16)30958-8_bib46) 2016; 17 Costa (10.1016/S0140-6736(16)30958-8_bib97) 2015; 33 Yankelevitz (10.1016/S0140-6736(16)30958-8_bib11) 2015; 277 Sequist (10.1016/S0140-6736(16)30958-8_bib76) 2011; 3 10.1016/S0140-6736(16)30958-8_bib139 Almquist (10.1016/S0140-6736(16)30958-8_bib116) 2016; 12 (10.1016/S0140-6736(16)30958-8_bib2) 2015 Rikova (10.1016/S0140-6736(16)30958-8_bib93) 2007; 131 Postow (10.1016/S0140-6736(16)30958-8_bib124) 2015; 33 Dearden (10.1016/S0140-6736(16)30958-8_bib110) 2013; 24 Westeel (10.1016/S0140-6736(16)30958-8_bib145) 2005; 97 Scagliotti (10.1016/S0140-6736(16)30958-8_bib107) 2015; 33 Wang (10.1016/S0140-6736(16)30958-8_bib105) 2012; 30 Doebele (10.1016/S0140-6736(16)30958-8_bib69) 2015; 5 Stahel (10.1016/S0140-6736(16)30958-8_bib90) 2015; 51 Mazières (10.1016/S0140-6736(16)30958-8_bib47) 2013; 31 Zou (10.1016/S0140-6736(16)30958-8_bib59) 2015; 112 Zhang (10.1016/S0140-6736(16)30958-8_bib150) 2011; 140 Rizvi (10.1016/S0140-6736(16)30958-8_bib129) 2015; 33 Garon (10.1016/S0140-6736(16)30958-8_bib132) 2015; 372 Henschke (10.1016/S0140-6736(16)30958-8_bib6) 2013; 158 Gettinger (10.1016/S0140-6736(16)30958-8_bib58) 2014; 25 Timmerman (10.1016/S0140-6736(16)30958-8_bib29) 2010; 303 Sequist (10.1016/S0140-6736(16)30958-8_bib73) 2013; 31 Califano (10.1016/S0140-6736(16)30958-8_bib66) 2015; 41 Cappuzzo (10.1016/S0140-6736(16)30958-8_bib143) 2010; 11 Kerr (10.1016/S0140-6736(16)30958-8_bib136) 2016; 140 Karachaliou (10.1016/S0140-6736(16)30958-8_bib87) 2015; 1 Herbst (10.1016/S0140-6736(16)30958-8_bib127) 2015; 387 Besse (10.1016/S0140-6736(16)30958-8_bib137) 2015; 51 Paz-Ares (10.1016/S0140-6736(16)30958-8_bib144) 2013; 31 Wu (10.1016/S0140-6736(16)30958-8_bib74) 2015; 26 Behera (10.1016/S0140-6736(16)30958-8_bib151) 2012; 77 Shaw (10.1016/S0140-6736(16)30958-8_bib101) 2016; 17 Fakiris (10.1016/S0140-6736(16)30958-8_bib30) 2009; 75 Bergethon (10.1016/S0140-6736(16)30958-8_bib60) 2012; 30 Kim (10.1016/S0140-6736(16)30958-8_bib96) 2012; 30 Gadgeel (10.1016/S0140-6736(16)30958-8_bib57) 2014; 15 Tan (10.1016/S0140-6736(16)30958-8_bib36) 2016; 11 Solomon (10.1016/S0140-6736(16)30958-8_bib55) 2014; 371 Garon (10.1016/S0140-6736(16)30958-8_bib117) 2014; 384 Flores (10.1016/S0140-6736(16)30958-8_bib13) 2014; 147 Perol (10.1016/S0140-6736(16)30958-8_bib149) 2012; 30 Bailar (10.1016/S0140-6736(16)30958-8_bib18) 1984; 130 10.1016/S0140-6736(16)30958-8_bib26 Ferlay (10.1016/S0140-6736(16)30958-8_bib1) 2015; 136 Drilon (10.1016/S0140-6736(16)30958-8_bib68) 2015; 33 Park (10.1016/S0140-6736(16)30958-8_bib78) 2015; 33 Thress (10.1016/S0140-6736(16)30958-8_bib83) 2015; 21 Camidge (10.1016/S0140-6736(16)30958-8_bib70) 2014; 32 Spigel (10.1016/S0140-6736(16)30958-8_bib108) 2014; 32 Piotrowska (10.1016/S0140-6736(16)30958-8_bib77) 2015; 5 Brahmer (10.1016/S0140-6736(16)30958-8_bib125) 2015; 373 Pinsky (10.1016/S0140-6736(16)30958-8_bib8) 2015; 162 Drilon (10.1016/S0140-6736(16)30958-8_bib67) 2013; 3 Weiss (10.1016/S0140-6736(16)30958-8_bib112) 2010; 2 Sequist (10.1016/S0140-6736(16)30958-8_bib40) 2015; 373 Goldstraw (10.1016/S0140-6736(16)30958-8_bib20) 2016; 11 Kris (10.1016/S0140-6736(16)30958-8_bib48) 2015; 26 Paik (10.1016/S0140-6736(16)30958-8_bib50) 2015; 5 Yang (10.1016/S0140-6736(16)30958-8_bib75) 2015; 16 Zhao (10.1016/S0140-6736(16)30958-8_bib152) 2015; 10 Awad (10.1016/S0140-6736(16)30958-8_bib64) 2013; 368 Rosell (10.1016/S0140-6736(16)30958-8_bib37) 2012; 13 Hirsch (10.1016/S0140-6736(16)30958-8_bib25) 2015; 12 Nokihara (10.1016/S0140-6736(16)30958-8_bib104) 2016; 34 Oxnard (10.1016/S0140-6736(16)30958-8_bib86) 2014; 20 Borghaei (10.1016/S0140-6736(16)30958-8_bib126) 2015; 373 Gettinger (10.1016/S0140-6736(16)30958-8_bib131) 2015; 33 Masters (10.1016/S0140-6736(16)30958-8_bib141) 2015; 33 Belani (10.1016/S0140-6736(16)30958-8_bib148) 2010; 28 Mitsudomi (10.1016/S0140-6736(16)30958-8_bib72) 2010; 11 Fehrenbacher (10.1016/S0140-6736(16)30958-8_bib128) 2016; 387 Fidias (10.1016/S0140-6736(16)30958-8_bib146) 2009; 27 Seto (10.1016/S0140-6736(16)30958-8_bib103) 2013; 14 Katayama (10.1016/S0140-6736(16)30958-8_bib52) 2015; 21 Field (10.1016/S0140-6736(16)30958-8_bib5) 2015; 71 Kazerooni (10.1016/S0140-6736(16)30958-8_bib7) 2015; 12 Planchard (10.1016/S0140-6736(16)30958-8_bib109) 2015; 33 Herbst (10.1016/S0140-6736(16)30958-8_bib134) 2014; 515 Mazières (10.1016/S0140-6736(16)30958-8_bib63) 2015; 33 (10.1016/S0140-6736(16)30958-8_bib119) 2015 Ostroff (10.1016/S0140-6736(16)30958-8_bib15) 2015; 18 Antonia (10.1016/S0140-6736(16)30958-8_bib138) 2015; 33 Bradley (10.1016/S0140-6736(16)30958-8_bib33) 2015; 16 Ramalingam (10.1016/S0140-6736(16)30958-8_bib140) 2011; 61 Felip (10.1016/S0140-6736(16)30958-8_bib102) 2015; 33 Jänne (10.1016/S0140-6736(16)30958-8_bib39) 2015; 372 Curran (10.1016/S0140-6736(16)30958-8_bib31) 2011; 103 Shaw (10.1016/S0140-6736(16)30958-8_bib51) 2009; 27 Frank (10.1016/S0140-6736(16)30958-8_bib9) 2013; 34 Sadiq (10.1016/S0140-6736(16)30958-8_bib49) 2013; 31 Friboulet (10.1016/S0140-6736(16)30958-8_bib99) 2014; 4 (10.1016/S0140-6736(16)30958-8_bib17) 2016; 188 Kwak (10.1016/S0140-6736(16)30958-8_bib94) 2010; 363 Boyle (10.1016/S0140-6736(16)30958-8_bib62) 2015; 16 Yang (10.1016/S0140-6736(16)30958-8_bib79) 2013; 79 Aberle (10.1016/S0140-6736(16)30958-8_bib3) 2011; 365 Villanti (10.1016/S0140-6736(16)30958-8_bib14) 2013; 8 Cao (10.1016/S0140-6736(16)30958-8_bib21) 2013; 16 Shaw (10.1016/S0140-6736(16)30958-8_bib54) 2013; 368 Michels (10.1016/S0140-6736(16)30958-8_bib106) 2016; 11 Auperin (10.1016/S0140-6736(16)30958-8_bib32) 2010; 28 Shaw (10.1016/S0140-6736(16)30958-8_bib61) 2014; 371 Forde (10.1016/S0140-6736(16)30958-8_bib120) 2014; 20 Quoix (10.1016/S0140-6736(16)30958-8_bib122) 2016; 17 Zeng (10.1016/S0140-6736(16)30958-8_bib91) 2015; 58 Reck (10.1016/S0140-6736(16)30958-8_bib118) 2014; 15 Horeweg (10.1016/S0140-6736(16)30958-8_bib4) 2014; 15 Pardoll (10.1016/S0140-6736(16)30958-8_bib123) 2012; 12 Mulshine (10.1016/S0140-6736(16)30958-8_bib12) 2014; 64 Zhou (10.1016/S0140-6736(16)30958-8_bib16) 2015; 6 Mazières (10.1016/S0140-6736(16)30958-8_bib42) 2013; 8 Shigematsu (10.1016/S0140-6736(16)30958-8_bib71) 2005; 97 Jänne (10.1016/S0140-6736(16)30958-8_bib41) 2013; 14 Paik (10.1016/S0140-6736(16)30958-8_bib44) 2011; 29 Ciuleanu (10.1016/S0140-6736(16)30958-8_bib142) 2009; 374 Rolfo (10.1016/S0140-6736(16)30958-8_bib65) 2014; 3 Mok (10.1016/S0140-6736(16)30958-8_bib100) 2015; 33 Soria (10.1016/S0140-6736(16)30958-8_bib82) 2015; 16 Brodowicz (10.1016/S0140-6736(16)30958-8_bib147) 2006; 52 Park (10.1016/S0140-6736(16)30958-8_bib38) 2016; 17 Soda (10.1016/S0140-6736(16)30958-8_bib92) 2007; 448 Goss (10.1016/S0140-6736(16)30958-8_bib27) 2013; 31 Gainor (10.1016/S0140-6736(16)30958-8_bib53) 2013; 19
References_xml	– volume: 1 start-page: 78 year: 2011 end-page: 89 ident: bib113 article-title: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer publication-title: Cancer Discov – volume: 19 start-page: 4273 year: 2013 end-page: 4281 ident: bib53 article-title: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer publication-title: Clin Cancer Res – volume: 17 start-page: 234 year: 2016 end-page: 242 ident: bib101 article-title: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial publication-title: Lancet Oncol – volume: 21 start-page: 2244 year: 2015 end-page: 2255 ident: bib115 article-title: Small cell lung cancer: will recent progress lead to improved outcomes? publication-title: Clin Cancer Res – volume: 188 start-page: 425 year: 2016 end-page: 432 ident: bib17 article-title: Recommendations on screening for lung cancer publication-title: CMAJ – volume: 31 start-page: 1997 year: 2013 end-page: 2003 ident: bib47 article-title: Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives publication-title: J Clin Oncol – volume: 11 start-page: 39 year: 2016 end-page: 51 ident: bib20 article-title: The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer publication-title: J Thorac Oncol – volume: 11 start-page: 946 year: 2016 end-page: 963 ident: bib36 article-title: The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive NSCLC: status in 2016 publication-title: J Thorac Oncol – volume: 448 start-page: 561 year: 2007 end-page: 566 ident: bib92 article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer publication-title: Nature – volume: 17 start-page: 577 year: 2016 end-page: 589 ident: bib38 article-title: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial publication-title: Lancet Oncol – volume: 26 start-page: 3552 year: 2008 end-page: 3559 ident: bib22 article-title: Lung adjuvant cisplatin evaluation: a pooled analysis from the LACE Collaborative Group publication-title: J Clin Oncol – volume: 16 start-page: 106 year: 2015 end-page: 111 ident: bib62 article-title: ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer publication-title: Clin Lung Cancer – volume: 373 start-page: 123 year: 2015 end-page: 135 ident: bib125 article-title: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer publication-title: N Engl J Med – volume: 365 start-page: 395 year: 2011 end-page: 409 ident: bib3 article-title: Reduced lung-cancer mortality with low-dose computed tomographic screening publication-title: N Engl J Med – volume: 30 start-page: 3516 year: 2012 end-page: 3524 ident: bib149 article-title: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 28 start-page: 7506 year: 2010 ident: bib148 article-title: Randomized trial of gemcitabine-carboplatin (G-Cb) therapy followed by gemcitabine (G) maintenance or best supportive care (BSC) in advanced NSCLC publication-title: J Clin Oncol – volume: 103 start-page: 1452 year: 2011 end-page: 1460 ident: bib31 article-title: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 publication-title: J Natl Cancer Inst – volume: 21 start-page: 2227 year: 2015 end-page: 2235 ident: bib52 article-title: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine publication-title: Clin Cancer Res – volume: 11 start-page: 122 year: 2016 end-page: 127 ident: bib106 article-title: Clinicopathological characteristics of RET rearranged lung cancer in European patients publication-title: J Thorac Oncol – volume: 277 start-page: 555 year: 2015 end-page: 564 ident: bib11 article-title: CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds publication-title: Radiology – volume: 21 start-page: 3196 year: 2015 end-page: 3203 ident: bib85 article-title: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy publication-title: Clin Cancer Res – volume: 20 start-page: 1698 year: 2014 end-page: 1705 ident: bib86 article-title: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA publication-title: Clin Cancer Res – volume: 33 start-page: 1881 year: 2015 end-page: 1888 ident: bib97 article-title: Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases publication-title: J Clin Oncol – volume: 33 start-page: 7503 year: 2015 ident: bib138 article-title: Phase I/II study of nivolumab with or without ipilimumab for the treatment of recurrent small cell lung cancer (SCLC): CA209.032 publication-title: J Clin Oncol – volume: 51 start-page: S711 year: 2015 end-page: S712 ident: bib90 article-title: A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial publication-title: Eur J Cancer – volume: 33 start-page: 3488 year: 2015 end-page: 3515 ident: bib141 article-title: Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update publication-title: J Clin Oncol – volume: 372 start-page: 1689 year: 2015 end-page: 1699 ident: bib39 article-title: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer publication-title: N Engl J Med – volume: 26 start-page: 1421 year: 2015 end-page: 1427 ident: bib48 article-title: Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors publication-title: Ann Oncol – volume: 10 start-page: 655 year: 2015 end-page: 664 ident: bib152 article-title: Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) publication-title: J Thorac Oncol – volume: 16 start-page: 244 year: 2013 end-page: 249 ident: bib21 article-title: Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients publication-title: Interact Cardiovasc Thorac Surg – volume: 370 start-page: 1189 year: 2014 end-page: 1197 ident: bib56 article-title: Ceritinib in ALK-rearranged non-small-cell lung cancer publication-title: N Engl J Med – volume: 30 start-page: 863 year: 2012 end-page: 870 ident: bib60 article-title: ROS1 rearrangements define a unique molecular class of lung cancers publication-title: J Clin Oncol – volume: 3 start-page: 250 year: 2014 end-page: 261 ident: bib65 article-title: ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it publication-title: Transl Lung Cancer Res – volume: 33 start-page: 1974 year: 2015 end-page: 1983 ident: bib124 article-title: Immune checkpoint blockade in cancer therapy publication-title: J Clin Oncol – volume: 11 start-page: 521 year: 2010 end-page: 529 ident: bib143 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study publication-title: Lancet Oncol – volume: 31 start-page: 3327 year: 2013 end-page: 3334 ident: bib73 article-title: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations publication-title: J Clin Oncol – volume: 13 start-page: 1011 year: 2012 end-page: 1019 ident: bib95 article-title: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study publication-title: Lancet Oncol – volume: 136 start-page: E359 year: 2015 end-page: E386 ident: bib1 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer – volume: 112 start-page: 3493 year: 2015 end-page: 3498 ident: bib59 article-title: PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations publication-title: Proc Natl Acad Sci USA – volume: 41 start-page: 401 year: 2015 end-page: 411 ident: bib66 article-title: Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer publication-title: Cancer Treat Rev – volume: 15 start-page: 143 year: 2014 end-page: 155 ident: bib118 article-title: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial publication-title: Lancet Oncol – volume: 21 start-page: 560 year: 2015 end-page: 562 ident: bib83 article-title: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M publication-title: Nat Med – volume: 3 start-page: 75ra26 year: 2011 ident: bib76 article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors publication-title: Sci Transl Med – volume: 16 start-page: 187 year: 2015 end-page: 199 ident: bib33 article-title: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel with or without cetuximab for patients with stage IIIA/IIIB non-small cell lung cancer: RTOG 0617 publication-title: Lancet Oncol – volume: 387 start-page: 1540 year: 2015 end-page: 1550 ident: bib127 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet – volume: 7 start-page: 1807 year: 2012 end-page: 1814 ident: bib80 article-title: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer publication-title: J Thorac Oncol – volume: 28 start-page: 2181 year: 2010 end-page: 2190 ident: bib32 article-title: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 32 start-page: 8000 year: 2014 ident: bib108 article-title: Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicentre, placebo-controlled METLung (OAM4971g) global trial publication-title: J Clin Oncol – volume: 371 start-page: 1963 year: 2014 end-page: 1971 ident: bib61 article-title: Crizotinib in ROS1-rearranged non-small-cell lung cancer publication-title: N Engl J Med – volume: 17 start-page: 822 year: 2016 end-page: 835 ident: bib121 article-title: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet – reference: Wakelee HA, Dahlberg SE, Keller SM, et-al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): Results of E1505. World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 1608. – year: June 16, 2016 ident: bib135 publication-title: Merck's KEYTRUDA (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer [news release] – volume: 4 start-page: 662 year: 2014 end-page: 673 ident: bib99 article-title: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer publication-title: Cancer Discov – volume: 2 start-page: 62ra93 year: 2010 ident: bib112 article-title: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer publication-title: Sci Transl Med – volume: 97 start-page: 499 year: 2005 end-page: 506 ident: bib145 article-title: Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer publication-title: J Natl Cancer Inst – volume: 2 start-page: 305 year: 2016 end-page: 312 ident: bib81 article-title: First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer: the ASPIRATION study publication-title: JAMA Oncol – year: 2015 ident: bib2 publication-title: Cancer facts & figures 2015 – volume: 31 start-page: 1089 year: 2013 end-page: 1096 ident: bib49 article-title: MET as a possible target for non-small-cell lung cancer publication-title: J Clin Oncol – volume: 27 start-page: 4247 year: 2009 end-page: 4253 ident: bib51 article-title: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK publication-title: J Clin Oncol – volume: 15 start-page: 1236 year: 2014 end-page: 1244 ident: bib89 article-title: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study publication-title: Lancet Oncol – volume: 33 start-page: 8059 year: 2015 ident: bib100 article-title: ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ) publication-title: J Clin Oncol – volume: 30 start-page: 7533 year: 2012 ident: bib96 article-title: Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer publication-title: J Clin Oncol – volume: 34 start-page: 9008 year: 2016 ident: bib104 article-title: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study publication-title: J Clin Oncol – volume: 33 start-page: 8006 year: 2015 ident: bib109 article-title: Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAFV600E mutated (mut) metastatic non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 58 start-page: 8200 year: 2015 end-page: 8215 ident: bib91 article-title: Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor publication-title: J Med Chem – volume: 15 start-page: 1119 year: 2014 end-page: 1128 ident: bib57 article-title: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study publication-title: Lancet Oncol – volume: 373 start-page: 578 year: 2015 end-page: 579 ident: bib40 article-title: Rociletinib in EGFR-mutated non-small-cell lung cancer publication-title: N Engl J Med – volume: 14 start-page: 590 year: 2013 end-page: 598 ident: bib103 article-title: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study publication-title: Lancet Oncol – volume: 384 start-page: 665 year: 2014 end-page: 673 ident: bib117 article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial publication-title: Lancet – volume: 27 start-page: 591 year: 2009 end-page: 598 ident: bib146 article-title: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 303 start-page: 1070 year: 2010 end-page: 1076 ident: bib29 article-title: Stereotactic body radiation therapy for inoperable early stage lung cancer publication-title: JAMA – volume: 24 start-page: 653 year: 2011 end-page: 664 ident: bib10 article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases publication-title: Mod Pathol – volume: 374 start-page: 1432 year: 2009 end-page: 1440 ident: bib142 article-title: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study publication-title: Lancet – volume: 34 start-page: 738 year: 2013 end-page: 747 ident: bib9 article-title: Radiation risk of lung cancer screening publication-title: Semin Respir Crit Care Med – volume: 17 start-page: 642 year: 2016 end-page: 650 ident: bib46 article-title: Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 11 start-page: 121 year: 2010 end-page: 128 ident: bib72 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial publication-title: Lancet Oncol – volume: 16 start-page: 830 year: 2015 end-page: 838 ident: bib75 article-title: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 publication-title: Lancet Oncol – volume: 18 start-page: 1472 year: 2012 end-page: 1482 ident: bib98 article-title: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer publication-title: Clin Cancer Res – volume: 25 start-page: 1462 year: 2014 end-page: 1474 ident: bib19 article-title: 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 489 start-page: 519 year: 2012 end-page: 525 ident: bib111 article-title: Comprehensive genomic characterization of squamous cell lung cancers publication-title: Nature – volume: 52 start-page: 155 year: 2006 end-page: 163 ident: bib147 article-title: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial publication-title: Lung Cancer – volume: 15 start-page: 1332 year: 2014 end-page: 1341 ident: bib4 article-title: Lung cancer probability in patients with CT-detected pulmonary nodules: a pre-specified analysis of data from the NELSON trial of low-dose CT screening publication-title: Lancet Oncol – volume: 4 start-page: 453 year: 2016 end-page: 474 ident: bib114 article-title: Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? publication-title: J Thorac Oncol – volume: 51 start-page: S717 year: 2015 end-page: S718 ident: bib137 article-title: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) publication-title: Eur J Cancer – volume: 11 start-page: 613 year: 2016 end-page: 638 ident: bib35 article-title: Scientific advances in lung cancer 2015 publication-title: J Thorac Oncol – volume: 26 start-page: 1883 year: 2015 end-page: 1889 ident: bib74 article-title: First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study publication-title: Ann Oncol – volume: 33 start-page: 8032 year: 2015 ident: bib129 article-title: Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 162 start-page: 485 year: 2015 end-page: 591 ident: bib8 article-title: Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment publication-title: Ann Intern Med – volume: 25 start-page: iv426 year: 2014 end-page: iv470 ident: bib58 article-title: ALK Inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data publication-title: Ann Oncol – volume: 16 start-page: 990 year: 2015 end-page: 998 ident: bib82 article-title: Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial publication-title: Lancet Oncol – volume: 77 start-page: 331 year: 2012 end-page: 338 ident: bib151 article-title: Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis publication-title: Lung Cancer – volume: 12 start-page: 38 year: 2015 end-page: 42 ident: bib7 article-title: ACR CT accreditation program and the lung cancer screening program designation publication-title: J Am Coll Radiol – volume: 17 start-page: 212 year: 2016 end-page: 223 ident: bib122 article-title: TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial publication-title: Lancet Oncol – reference: Alley EW, Schellens JH, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). IASLC 16th World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 3011. – volume: 158 start-page: 246 year: 2013 end-page: 252 ident: bib6 article-title: Definition of a positive test result in computed tomography screening for lung cancer: a cohort study publication-title: Ann Intern Med – volume: 12 start-page: 689 year: 2015 end-page: 690 ident: bib25 article-title: Adjuvant TKIs in NSCLC: what can we learn from RADIANT? publication-title: Nat Rev Clin Oncol – volume: 368 start-page: 2385 year: 2013 end-page: 2394 ident: bib54 article-title: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer publication-title: N Engl J Med – volume: 24 start-page: 2371 year: 2013 end-page: 2376 ident: bib110 article-title: Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) publication-title: Ann Oncol – volume: 373 start-page: 1627 year: 2015 end-page: 1639 ident: bib126 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med – volume: 372 start-page: 2018 year: 2015 end-page: 2028 ident: bib132 article-title: Pembrolizumab for the treatment of non-small-cell lung cancer publication-title: N Engl J Med – volume: 371 start-page: 2167 year: 2014 end-page: 2177 ident: bib55 article-title: Firstline crizotinib versus chemotherapy in ALK-positive lung cancer publication-title: N Engl J Med – volume: 33 start-page: 8084 year: 2015 ident: bib78 article-title: Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI) publication-title: J Clin Oncol – volume: 1 start-page: 149 year: 2015 end-page: 157 ident: bib87 article-title: Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial publication-title: JAMA Oncol – volume: 383 start-page: 1561 year: 2014 end-page: 1571 ident: bib23 article-title: Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data publication-title: Lancet – ident: bib28 article-title: ALCHEMIST (Adjuvant Lung Cancer Enhancement Marker Identification and Sequencing Trials) – volume: 33 start-page: 8060 year: 2015 ident: bib102 article-title: ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 14 start-page: 38 year: 2013 end-page: 47 ident: bib41 article-title: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study publication-title: Lancet Oncol – volume: 5 start-page: 713 year: 2015 end-page: 722 ident: bib77 article-title: Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor publication-title: Cancer Discov – volume: 34 start-page: 953 year: 2016 end-page: 962 ident: bib34 article-title: PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol – volume: 32 start-page: 8001 year: 2014 ident: bib70 article-title: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 31 start-page: 2895 year: 2013 end-page: 2902 ident: bib144 article-title: PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer publication-title: J Clin Oncol – volume: 33 start-page: 992 year: 2015 end-page: 999 ident: bib63 article-title: Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort publication-title: J Clin Oncol – volume: 515 start-page: 563 year: 2014 end-page: 567 ident: bib134 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature – volume: 147 start-page: 1619 year: 2014 end-page: 1626 ident: bib13 article-title: Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer publication-title: J Thorac Cardiovasc Surg – volume: 97 start-page: 339 year: 2005 end-page: 346 ident: bib71 article-title: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers publication-title: J Natl Cancer Inst – volume: 79 start-page: 33 year: 2013 end-page: 39 ident: bib79 article-title: Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer publication-title: Lung Cancer – volume: 130 start-page: 541 year: 1984 end-page: 542 ident: bib18 article-title: Screening for lung cancer—where are we now? publication-title: Am Rev Respir Dis – volume: 21 start-page: 3913 year: 2015 end-page: 3923 ident: bib84 article-title: EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors publication-title: Clin Cancer Res – volume: 33 start-page: 8007 year: 2015 ident: bib68 article-title: Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers publication-title: J Clin Oncol – volume: 12 start-page: 252 year: 2012 end-page: 264 ident: bib123 article-title: The blockade of immune checkpoints in cancer immunotherapy publication-title: Nat Rev Cancer – volume: 8 start-page: e71379 year: 2013 ident: bib14 article-title: A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions publication-title: PLoS One – volume: 33 start-page: 2667 year: 2015 end-page: 2674 ident: bib107 article-title: Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol – volume: 30 start-page: 4352 year: 2012 end-page: 4359 ident: bib105 article-title: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer publication-title: J Clin Oncol – volume: 140 start-page: 326 year: 2016 end-page: 331 ident: bib136 article-title: Programmed Death Ligand 1 immunohistochemistry: friend or foe? publication-title: Arch Pathol Lab Med – volume: 12 start-page: 111 year: 2016 end-page: 117 ident: bib116 article-title: Multimodality therapy for limited-stage small-cell lung cancer publication-title: J Oncol Pract – volume: 29 start-page: 3574 year: 2011 end-page: 3579 ident: bib43 article-title: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations publication-title: J Clin Oncol – volume: 131 start-page: 1190 year: 2007 end-page: 1203 ident: bib93 article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer publication-title: Cell – volume: 387 start-page: 1837 year: 2016 end-page: 1846 ident: bib128 article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial publication-title: Lancet – volume: 13 start-page: 239 year: 2012 end-page: 246 ident: bib37 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol – volume: 33 start-page: 4007 year: 2015 end-page: 4014 ident: bib24 article-title: Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial publication-title: J Clin Oncol – volume: 29 start-page: 2046 year: 2011 end-page: 2051 ident: bib44 article-title: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations publication-title: J Clin Oncol – volume: 64 start-page: 352 year: 2014 end-page: 363 ident: bib12 article-title: Issues with implementing a high-quality lung cancer screening program publication-title: CA Cancer J Clin – volume: 71 start-page: 161 year: 2015 end-page: 170 ident: bib5 article-title: UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening publication-title: Thorax – volume: 75 start-page: 677 year: 2009 end-page: 682 ident: bib30 article-title: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study publication-title: Int J Radiat Oncol Biol Phys – volume: 5 start-page: 842 year: 2015 end-page: 849 ident: bib50 article-title: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping publication-title: Cancer Discov – volume: 20 start-page: 1067 year: 2014 end-page: 1073 ident: bib120 article-title: New strategies in lung cancer: translating immunotherapy into clinical practice publication-title: Clin Cancer Res – volume: 8 start-page: 2922 year: 2013 ident: bib42 article-title: Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results publication-title: J Thorac Oncol – volume: 373 start-page: 726 year: 2015 end-page: 736 ident: bib45 article-title: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations publication-title: N Engl J Med – volume: 3 start-page: 630 year: 2013 end-page: 635 ident: bib67 article-title: Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas publication-title: Cancer Discov – volume: 31 start-page: 3320 year: 2013 end-page: 3326 ident: bib27 article-title: Gefitinib versus placebo in completely resected non-small cell lung cancer; result of the NCIC-CTG BR 19 study publication-title: J Clin Oncol – volume: 26 start-page: 33LBA year: 2015 ident: bib133 article-title: Efficacy and safety of pembrolizumab (Pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001 publication-title: Ann Oncol – volume: 5 start-page: 1049 year: 2015 end-page: 1057 ident: bib69 article-title: An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101 publication-title: Cancer Discov – volume: 140 start-page: 117 year: 2011 end-page: 126 ident: bib150 article-title: Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis publication-title: Chest – volume: 368 start-page: 2395 year: 2013 end-page: 2401 ident: bib64 article-title: Acquired resistance to crizotinib from a mutation in CD74-ROS1 publication-title: N Engl J Med – volume: 14 start-page: 777 year: 2013 end-page: 786 ident: bib88 article-title: Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial publication-title: Lancet Oncol – volume: 18 start-page: 1067 year: 2015 end-page: 1075 ident: bib15 article-title: Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers publication-title: Nicotine Tob Res – volume: 6 start-page: 812 year: 2015 end-page: 818 ident: bib16 article-title: China national lung cancer screening guideline with low-dose computed tomography (2015 version) publication-title: Thorac Cancer – year: Dec 17, 2015 ident: bib119 publication-title: Summary of opinion: Portrazza – volume: 363 start-page: 1693 year: 2010 end-page: 1703 ident: bib94 article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer publication-title: N Engl J Med – volume: 33 start-page: 2004 year: 2015 end-page: 2012 ident: bib131 article-title: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 61 start-page: 91 year: 2011 end-page: 112 ident: bib140 article-title: Lung cancer: new biological insights and recent therapeutic advances publication-title: CA Cancer J Clin – volume: 33 start-page: 8034 year: 2015 ident: bib130 article-title: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy publication-title: J Clin Oncol – volume: 31 start-page: 1997 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib47 article-title: Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.6095 – volume: 277 start-page: 555 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib11 article-title: CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds publication-title: Radiology doi: 10.1148/radiol.2015142554 – volume: 32 start-page: 8000 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib108 article-title: Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicentre, placebo-controlled METLung (OAM4971g) global trial publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.8000 – volume: 515 start-page: 563 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib134 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature doi: 10.1038/nature14011 – volume: 140 start-page: 117 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib150 article-title: Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis publication-title: Chest doi: 10.1378/chest.10-2745 – volume: 28 start-page: 7506 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib148 article-title: Randomized trial of gemcitabine-carboplatin (G-Cb) therapy followed by gemcitabine (G) maintenance or best supportive care (BSC) in advanced NSCLC publication-title: J Clin Oncol doi: 10.1200/jco.2010.28.15_suppl.7506 – volume: 17 start-page: 822 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib121 article-title: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S1470-2045(16)00099-1 – volume: 13 start-page: 1011 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib95 article-title: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70344-3 – ident: 10.1016/S0140-6736(16)30958-8_bib139 – volume: 29 start-page: 2046 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib44 article-title: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.1280 – volume: 11 start-page: 122 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib106 article-title: Clinicopathological characteristics of RET rearranged lung cancer in European patients publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.09.016 – volume: 31 start-page: 3327 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib73 article-title: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.2806 – volume: 3 start-page: 250 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib65 article-title: ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it publication-title: Transl Lung Cancer Res – volume: 16 start-page: 990 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib82 article-title: Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00121-7 – volume: 140 start-page: 326 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib136 article-title: Programmed Death Ligand 1 immunohistochemistry: friend or foe? publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2015-0522-SA – volume: 8 start-page: e71379 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib14 article-title: A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions publication-title: PLoS One doi: 10.1371/journal.pone.0071379 – volume: 11 start-page: 121 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib72 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70364-X – volume: 19 start-page: 4273 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib53 article-title: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0318 – volume: 51 start-page: S711 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib90 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(15)30068-X – volume: 26 start-page: 1421 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib48 article-title: Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors publication-title: Ann Oncol doi: 10.1093/annonc/mdv186 – volume: 25 start-page: 1462 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib19 article-title: 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdu089 – volume: 16 start-page: 187 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib33 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71207-0 – volume: 15 start-page: 1332 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib4 article-title: Lung cancer probability in patients with CT-detected pulmonary nodules: a pre-specified analysis of data from the NELSON trial of low-dose CT screening publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70389-4 – volume: 303 start-page: 1070 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib29 article-title: Stereotactic body radiation therapy for inoperable early stage lung cancer publication-title: JAMA doi: 10.1001/jama.2010.261 – volume: 130 start-page: 541 year: 1984 ident: 10.1016/S0140-6736(16)30958-8_bib18 article-title: Screening for lung cancer—where are we now? publication-title: Am Rev Respir Dis – volume: 79 start-page: 33 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib79 article-title: Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.09.016 – volume: 34 start-page: 738 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib9 article-title: Radiation risk of lung cancer screening publication-title: Semin Respir Crit Care Med doi: 10.1055/s-0033-1358615 – volume: 21 start-page: 560 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib83 article-title: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M publication-title: Nat Med doi: 10.1038/nm.3854 – volume: 147 start-page: 1619 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib13 article-title: Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2013.11.001 – volume: 25 start-page: iv426 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib58 article-title: ALK Inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data publication-title: Ann Oncol doi: 10.1093/annonc/mdu349.71 – volume: 7 start-page: 1807 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib80 article-title: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3182745948 – year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib2 – volume: 12 start-page: 111 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib116 article-title: Multimodality therapy for limited-stage small-cell lung cancer publication-title: J Oncol Pract doi: 10.1200/JOP.2015.009068 – volume: 14 start-page: 38 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib41 article-title: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70489-8 – volume: 20 start-page: 1698 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib86 article-title: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-2482 – volume: 33 start-page: 8060 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib102 article-title: ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8060 – volume: 368 start-page: 2385 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib54 article-title: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1214886 – volume: 21 start-page: 3913 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib84 article-title: EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2789 – volume: 27 start-page: 4247 year: 2009 ident: 10.1016/S0140-6736(16)30958-8_bib51 article-title: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK publication-title: J Clin Oncol doi: 10.1200/JCO.2009.22.6993 – volume: 363 start-page: 1693 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib94 article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1006448 – volume: 31 start-page: 2895 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib144 article-title: PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.47.1102 – volume: 162 start-page: 485 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib8 article-title: Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment publication-title: Ann Intern Med doi: 10.7326/M14-2086 – volume: 27 start-page: 591 year: 2009 ident: 10.1016/S0140-6736(16)30958-8_bib146 article-title: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.1405 – volume: 15 start-page: 1236 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib89 article-title: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70381-X – volume: 17 start-page: 577 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib38 article-title: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30033-X – volume: 33 start-page: 8084 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib78 article-title: Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI) publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8084 – volume: 61 start-page: 91 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib140 article-title: Lung cancer: new biological insights and recent therapeutic advances publication-title: CA Cancer J Clin doi: 10.3322/caac.20102 – volume: 33 start-page: 2004 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib131 article-title: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.3708 – volume: 12 start-page: 252 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib123 article-title: The blockade of immune checkpoints in cancer immunotherapy publication-title: Nat Rev Cancer doi: 10.1038/nrc3239 – volume: 29 start-page: 3574 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib43 article-title: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.9638 – volume: 373 start-page: 726 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib45 article-title: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations publication-title: N Engl J Med doi: 10.1056/NEJMoa1502309 – volume: 12 start-page: 689 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib25 article-title: Adjuvant TKIs in NSCLC: what can we learn from RADIANT? publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2015.202 – volume: 21 start-page: 3196 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib85 article-title: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2594 – volume: 26 start-page: 3552 year: 2008 ident: 10.1016/S0140-6736(16)30958-8_bib22 article-title: Lung adjuvant cisplatin evaluation: a pooled analysis from the LACE Collaborative Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.9030 – volume: 372 start-page: 1689 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib39 article-title: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1411817 – volume: 31 start-page: 3320 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib27 article-title: Gefitinib versus placebo in completely resected non-small cell lung cancer; result of the NCIC-CTG BR 19 study publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.1816 – volume: 6 start-page: 812 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib16 article-title: China national lung cancer screening guideline with low-dose computed tomography (2015 version) publication-title: Thorac Cancer doi: 10.1111/1759-7714.12287 – volume: 33 start-page: 1881 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib97 article-title: Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2014.59.0539 – volume: 387 start-page: 1540 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib127 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 33 start-page: 1974 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib124 article-title: Immune checkpoint blockade in cancer therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2014.59.4358 – volume: 373 start-page: 578 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib40 article-title: Rociletinib in EGFR-mutated non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMc1506831 – volume: 18 start-page: 1067 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib15 article-title: Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers publication-title: Nicotine Tob Res doi: 10.1093/ntr/ntv177 – volume: 131 start-page: 1190 year: 2007 ident: 10.1016/S0140-6736(16)30958-8_bib93 article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer publication-title: Cell doi: 10.1016/j.cell.2007.11.025 – volume: 2 start-page: 305 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib81 article-title: First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer: the ASPIRATION study publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.4921 – volume: 4 start-page: 662 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib99 article-title: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0846 – volume: 365 start-page: 395 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib3 article-title: Reduced lung-cancer mortality with low-dose computed tomographic screening publication-title: N Engl J Med doi: 10.1056/NEJMoa1102873 – volume: 112 start-page: 3493 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib59 article-title: PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1420785112 – volume: 371 start-page: 1963 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib61 article-title: Crizotinib in ROS1-rearranged non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1406766 – volume: 33 start-page: 8034 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib130 article-title: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8034 – volume: 33 start-page: 4007 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib24 article-title: Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.8918 – volume: 30 start-page: 863 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib60 article-title: ROS1 rearrangements define a unique molecular class of lung cancers publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.6345 – volume: 33 start-page: 3488 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib141 article-title: Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update publication-title: J Clin Oncol doi: 10.1200/JCO.2015.62.1342 – volume: 373 start-page: 123 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib125 article-title: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 – volume: 11 start-page: 39 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib20 article-title: The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2015.09.009 – volume: 373 start-page: 1627 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib126 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 – volume: 33 start-page: 7503 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib138 article-title: Phase I/II study of nivolumab with or without ipilimumab for the treatment of recurrent small cell lung cancer (SCLC): CA209.032 publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.7503 – volume: 52 start-page: 155 year: 2006 ident: 10.1016/S0140-6736(16)30958-8_bib147 article-title: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.01.006 – volume: 21 start-page: 2227 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib52 article-title: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2791 – volume: 14 start-page: 777 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib88 article-title: Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70254-7 – volume: 5 start-page: 713 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib77 article-title: Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-0399 – volume: 51 start-page: S717 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib137 article-title: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) publication-title: Eur J Cancer doi: 10.1016/S0959-8049(16)31938-4 – volume: 24 start-page: 653 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib10 article-title: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases publication-title: Mod Pathol doi: 10.1038/modpathol.2010.232 – volume: 13 start-page: 239 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib37 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70393-X – volume: 383 start-page: 1561 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib23 article-title: Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data publication-title: Lancet doi: 10.1016/S0140-6736(13)62159-5 – volume: 41 start-page: 401 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib66 article-title: Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.03.009 – volume: 26 start-page: 1883 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib74 article-title: First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study publication-title: Ann Oncol doi: 10.1093/annonc/mdv270 – volume: 16 start-page: 106 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib62 article-title: ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2014.10.003 – volume: 448 start-page: 561 year: 2007 ident: 10.1016/S0140-6736(16)30958-8_bib92 article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer publication-title: Nature doi: 10.1038/nature05945 – volume: 368 start-page: 2395 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib64 article-title: Acquired resistance to crizotinib from a mutation in CD74-ROS1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1215530 – volume: 33 start-page: 8007 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib68 article-title: Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8007 – volume: 10 start-page: 655 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib152 article-title: Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000445 – volume: 17 start-page: 212 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib122 article-title: TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00483-0 – volume: 16 start-page: 244 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib21 article-title: Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients publication-title: Interact Cardiovasc Thorac Surg doi: 10.1093/icvts/ivs472 – volume: 33 start-page: 8059 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib100 article-title: ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ) publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8059 – volume: 75 start-page: 677 year: 2009 ident: 10.1016/S0140-6736(16)30958-8_bib30 article-title: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.11.042 – volume: 3 start-page: 630 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib67 article-title: Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0035 – volume: 374 start-page: 1432 year: 2009 ident: 10.1016/S0140-6736(16)30958-8_bib142 article-title: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(09)61497-5 – volume: 33 start-page: 8006 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib109 article-title: Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAFV600E mutated (mut) metastatic non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8006 – volume: 5 start-page: 842 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib50 article-title: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-14-1467 – volume: 30 start-page: 7533 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib96 article-title: Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.39.9766 – volume: 30 start-page: 3516 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib149 article-title: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.39.9782 – volume: 158 start-page: 246 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib6 article-title: Definition of a positive test result in computed tomography screening for lung cancer: a cohort study publication-title: Ann Intern Med doi: 10.7326/0003-4819-158-4-201302190-00004 – volume: 11 start-page: 613 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib35 article-title: Scientific advances in lung cancer 2015 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.03.012 – volume: 3 start-page: 75ra26 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib76 article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002003 – volume: 64 start-page: 352 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib12 article-title: Issues with implementing a high-quality lung cancer screening program publication-title: CA Cancer J Clin doi: 10.3322/caac.21239 – volume: 4 start-page: 453 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib114 article-title: Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.01.012 – volume: 5 start-page: 1049 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib69 article-title: An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-0443 – volume: 2 start-page: 62ra93 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib112 article-title: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3001451 – volume: 97 start-page: 499 year: 2005 ident: 10.1016/S0140-6736(16)30958-8_bib145 article-title: Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji096 – volume: 71 start-page: 161 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib5 article-title: UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening publication-title: Thorax doi: 10.1136/thoraxjnl-2015-207140 – volume: 33 start-page: 992 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib63 article-title: Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.3302 – volume: 97 start-page: 339 year: 2005 ident: 10.1016/S0140-6736(16)30958-8_bib71 article-title: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji055 – volume: 371 start-page: 2167 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib55 article-title: Firstline crizotinib versus chemotherapy in ALK-positive lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1408440 – volume: 21 start-page: 2244 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib115 article-title: Small cell lung cancer: will recent progress lead to improved outcomes? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2958 – volume: 11 start-page: 521 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib143 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70112-1 – volume: 136 start-page: E359 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib1 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer doi: 10.1002/ijc.29210 – volume: 58 start-page: 8200 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib91 article-title: Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b01073 – volume: 17 start-page: 234 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib101 article-title: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00488-X – volume: 34 start-page: 9008 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib104 article-title: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study publication-title: J Clin Oncol doi: 10.1200/JCO.2016.34.15_suppl.9008 – volume: 372 start-page: 2018 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib132 article-title: Pembrolizumab for the treatment of non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1501824 – ident: 10.1016/S0140-6736(16)30958-8_bib26 – volume: 384 start-page: 665 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib117 article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(14)60845-X – volume: 489 start-page: 519 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib111 article-title: Comprehensive genomic characterization of squamous cell lung cancers publication-title: Nature doi: 10.1038/nature11404 – volume: 18 start-page: 1472 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib98 article-title: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2906 – volume: 387 start-page: 1837 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib128 article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00587-0 – volume: 370 start-page: 1189 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib56 article-title: Ceritinib in ALK-rearranged non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1311107 – volume: 15 start-page: 143 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib118 article-title: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70586-2 – volume: 33 start-page: 2667 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib107 article-title: Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2014.60.7317 – volume: 77 start-page: 331 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib151 article-title: Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.03.019 – year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib135 – volume: 103 start-page: 1452 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib31 article-title: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr325 – volume: 8 start-page: 2922 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib42 article-title: Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results publication-title: J Thorac Oncol – volume: 1 start-page: 149 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib87 article-title: Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2014.257 – volume: 34 start-page: 953 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib34 article-title: PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2015.64.8824 – volume: 17 start-page: 642 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib46 article-title: Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)00077-2 – volume: 28 start-page: 2181 year: 2010 ident: 10.1016/S0140-6736(16)30958-8_bib32 article-title: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.2543 – volume: 11 start-page: 946 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib36 article-title: The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive NSCLC: status in 2016 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.05.008 – volume: 31 start-page: 1089 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib49 article-title: MET as a possible target for non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.9422 – volume: 15 start-page: 1119 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib57 article-title: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70362-6 – volume: 16 start-page: 830 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib75 article-title: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00026-1 – volume: 12 start-page: 38 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib7 article-title: ACR CT accreditation program and the lung cancer screening program designation publication-title: J Am Coll Radiol doi: 10.1016/j.jacr.2014.10.002 – volume: 24 start-page: 2371 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib110 article-title: Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) publication-title: Ann Oncol doi: 10.1093/annonc/mdt205 – volume: 1 start-page: 78 year: 2011 ident: 10.1016/S0140-6736(16)30958-8_bib113 article-title: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer publication-title: Cancer Discov doi: 10.1158/2159-8274.CD-11-0005 – volume: 14 start-page: 590 year: 2013 ident: 10.1016/S0140-6736(16)30958-8_bib103 article-title: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70142-6 – volume: 188 start-page: 425 year: 2016 ident: 10.1016/S0140-6736(16)30958-8_bib17 article-title: Recommendations on screening for lung cancer publication-title: CMAJ doi: 10.1503/cmaj.151421 – volume: 20 start-page: 1067 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib120 article-title: New strategies in lung cancer: translating immunotherapy into clinical practice publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0731 – volume: 26 start-page: 33LBA year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib133 article-title: Efficacy and safety of pembrolizumab (Pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001 publication-title: Ann Oncol – volume: 32 start-page: 8001 year: 2014 ident: 10.1016/S0140-6736(16)30958-8_bib70 article-title: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.8001 – volume: 30 start-page: 4352 year: 2012 ident: 10.1016/S0140-6736(16)30958-8_bib105 article-title: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.1477 – volume: 33 start-page: 8032 year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib129 article-title: Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.8032 – year: 2015 ident: 10.1016/S0140-6736(16)30958-8_bib119
SSID	ssj0004605
Score	2.6972795
SecondaryResourceType	review_article
Snippet	Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million... Summary Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	299
SubjectTerms	Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Combined Modality Therapy Early Detection of Cancer Humans Immunotherapy Internal Medicine Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - therapy Medical screening Mutation Oncology Prevention Survival Survival Rate
Title	Lung cancer: current therapies and new targeted treatments
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0140673616309588 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673616309588 https://dx.doi.org/10.1016/S0140-6736(16)30958-8 https://www.ncbi.nlm.nih.gov/pubmed/27574741 https://www.proquest.com/docview/1861147179 https://www.proquest.com/docview/1859723161
Volume	389
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1LS8QwEMcHXUG8iG_XFxE86KHaR171IiqKiIqoC3sL2aQ9SXfd7n5_J23avayPS2Hb_beQzkx-aSYZgBO0C0FzmqCniSSgLBdBGkobJBQVgqfRIHTrnZ9f-EOPPvZZ339wK31aZRMTq0Bth8Z9I7-IJEd0x8FHejX6ClzVKDe76ktoLMKS27rMWbXoi3nrIqsU99kKnov39uRpxM8SBA0ZyJ_6pp_Ys-qD7tdg1cMjua7f9josZMUGLD_76fFNuHxC1yXGvcjxJTH11kukXmKFI2KiC0sQo0md_p1Z0qaZl1vQu7_7uH0IfHGEwHDJXAn5xFqqmckTxwySUqt5mCcDyfGcDEVmEmSTVMQmFhr7ba2zONbMIlJzg-C1DZ1iWGS7QEKM12EumGFpSnMpB8wiFWqNZGeQ73gXaNMsyvidw10Bi081J0UMf1WtqWQXzlvZqN464y8Bb9pcNetCMZIpDO5_CcU8YVZ6fyxVpMpYhbXaiZFCnRSVslV65KhR4j8PPWjMQs2e01ppF47by-ixbhpGF9lw6v7DXKk3RO0u7NTm1LZPLBiO72i09_vN92EldngRRkEcHUBnMp5mhwhHk8FR5QF4lLfRESzd3L28vn0DiegE8g
linkProvider	ProQuest
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RkNpeqtLntpS6Uiu1h5TE7yBVFYKipexyKUjcjNd2TlWWElDVP8VvZBwn4bIULhzj5HOkyTw-xzMegI-oF4pXnKGlKZZxUamszLXPGEeEkmUxy2O98_RAjo_4z2NxvASXfS1MTKvsfWLrqP3cxX_kG4WWSN1x8VF-P_2Txa5RcXe1b6GR1GI__PuLS7bm294Oft9PlO7-ONweZ11XgcxJLWLvdeY9t8JVLAZbzbm3Mq_YTEsc07kKjmFQLxV1VFkMeNYGSq3wyEWlQ8aC8z6AFc7QNGNl-naxqA6zTam_rhja-DUMfi7kF4bERmf6plh4E9dtY97uU3jSkVWylbRrFZZC_QweTrvt-OewOUFXQVxUnLNN4tJRTySVdOEKnNjaE6TtJKWbB0-GtPbmBRzdi9hewnI9r8NrIDnGh7xSwomy5JXWM-GRhVqLTNIhn5Qj4L1YjOtOKo8NM36bBSlpeNVK0-gRfB1gp-mojtsAspe56etQ0XMaDCa3AdUiYGg6-29MYRpq8oSOYGS9EYpIPSA7ipOoy11eutarhbl-z2AVI_gw3EYPEbd9bB3mF_EZEVvLIbUfwaukToN8qBK4nuTFm_9P_h4ejQ-nEzPZO9h_C49ppDZ5kdFiDZbPzy7COyRm57P11hoInNy3-V0Bc1s95A
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RkFAvVUtfS2lxpVZqD-kmfgepqipgBeWhSi0SN9drO6cqCwRU9a_x6xjHSbgsjwvHOPkcaTKPz_GMB-AD6oXiFWdoaYplXFQqK3PtM8YRoWRZTPNY73xwKHeO-I9jcbwAl30tTEyr7H1i66j9zMV_5ONCS6TuuPgox1WXFvFza_Lt5DSLHaTiTmvfTiOpyF74_w-Xb83X3S381h8pnWz_3tzJug4DmZNaxD7szHtuhatYDLyac29lXrGpljimcxUcwwBfKuqoshj8rA2UWuGRl0qH7AXnfQRLiikdbUxvFvNqMtv0-uvqofGvYfBTIT8zJDk60zfFxZt4bxv_Jk_hSUdcyfekac9gIdQrsHzQbc0_h419dBvERSU62yAuHftEUnkXrsaJrT1BCk9S6nnwZEhxb17A0YOI7SUs1rM6vAaSY6zIKyWcKEteaT0VHhmptcgqHXJLOQLei8W47tTy2Dzjr5mTnoZXrTSNHsGXAXaSju24CyB7mZu-JhW9qMHAchdQzQOGpvMFjSlMQ02e0BGMDDhCEakHZEd3Eo25z0vXerUw1-8ZLGQE74fb6C3iFpCtw-wiPiNimzmk-SN4ldRpkA9VAteWvFi9ffJ1WEbDM_u7h3tv4DGNLCcvMlqsweL52UV4ixztfPquNQYCfx7a-q4A1mJCGg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lung+cancer%3A+current+therapies+and+new+targeted+treatments&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Hirsch%2C+Fred+R&rft.au=Scagliotti%2C+Giorgio+V&rft.au=Mulshine%2C+James+L&rft.au=Kwon%2C+Regina&rft.date=2017-01-21&rft.pub=Elsevier+Limited&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=389&rft.issue=10066&rft.spage=299&rft_id=info:doi/10.1016%2FS0140-6736%2816%2930958-8&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4307167481
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673617X00032%2Fcov150h.gif